2017N352027_00 CONFIDENTIA L
GlaxoSmithKline group of companies BTZ117352
1TITLE PA GE
Protocol Title: A Phase I, Open -Label, Single -Dose, Two-Part Study  to Assess the 
Pharmacokinetics of Gepotidacin ([COMPANY_004]2140944) in Male and Female Adult Participants
with Vary ing Degrees of Hepatic Impairment and in Matched Control Participants with 
Normal Hepatic Function
Protocol Number : BTZ117352
Short Title : Pharmacokinetics Study of Gepotidacin ([COMPANY_004]2140944) in Adult 
Participants with Vary ing Degrees of Hepatic Impairment and in Matched Control 
Participants with Normal Hepatic Function
Compound Number: [COMPANY_004]2140944
Sponsor Name [CONTACT_29560]: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_303095] Information
 MD
[COMPANY_003]
7551 Metro Center Driv e, Suite 300
Austin, TX [ZIP_CODE]
Safety  Hotline (24 hours): 
Safety  Fax Number: 
Email: 
Secondary  Medical Monitor
 MD
GlaxoSmithKline
[ADDRESS_303096]
Collegeville, PA [ZIP_CODE]
Telephon
e Number:  (primary ) or  (after business hours)
Fax Number: 
Regulat ory Agency Identifying Number :IND 111885
Approval Date: 15-FEB -2018
Copy right 2018 the GlaxoSmithKline group of companies. All rights reserved . 
Unauthorised cop ying or use of this information is prohibited. 2018N388749_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
 2018N388749_00
[COMPANY_003]
[COMPANY_003]
2017N352027_00 CONFID ENTIA L
BTZ117352
3TABLE OF CONTENTS
PAGE
1.SYNOPSIS ............................................................................................................... 6
2.SCHEDULE OF ACTIVITI ES (SOA) ....................................................................... 10
3.INTRODUCTION .................................................................................................... 13
3.1. Study Rationale .......................................................................................... 13
3.2.Background ................................................................................................ 13
3.3. Benefit/Risk Assessment ............................................................................ 13
3.3.1. Risk Assessment ......................................................................... 14
3.3.2. Benefit Assessment ..................................................................... 16
3.3.3. Overall Benefit:Risk Concl usion ................................................... 16
4.OBJECTIVES AND ENDPO INTS ........................................................................... 16
5.STUDY DESIGN .................................................................................................... 17
5.1. Overall Design ............................................................................................ 17
5.2. Number of Participants ............................................................................... 19
5.3. Participant and Study Completion ............................................................... 19
5.4. Scientific Rationale for Study Design .......................................................... 19
5.5. Dose Justification ........................................................................................ 19
6.STUDY POPULATION ........................................................................................... 20
6.1. Inclusion Criteria ......................................................................................... 20
6.2. Exclusion Criteria ........................................................................................ 21
6.3. Lifestyle Restrictions ................................................................................... 24
6.3.1. Meals and Dietary Restrictions .................................................... 24
6.3.2. Caffeine, Alcohol, and Tobacco ................................................... 25
6.3.3. Activity ......................................................................................... 25
6.4. Screen Failures ........................................................................................... 25
7.TREATMENTS ....................................................................................................... 26
7.1. Treatments Administered ............................................................................ 26
7.2. Dose Modification ....................................................................................... 26
7.3. Method of Treatment Assignment ............................................................... 26
7.4. Blinding ....................................................................................................... 28
7.5. Preparation/Handling/Storage/Accountability .............................................. 28
7.6. Treatment Compliance................................................................................ 28
7.7. Concomitant Therapy .................................................................................. 28
7.7.1. Permitted Therapy ....................................................................... 29
7.7.2. Prohibited Therapy ...................................................................... 29
7.8. Treatment after the End of the Study .......................................................... 29
8.DISCONTINUATION CRIT ERIA ............................................................................. 30
8.1. Discontinuation of Study Treatment ............................................................ 30
8.1.1. Liver Chemistry Evaluation Criteria .............................................. 30
8.1.2. QTc Evaluation Criteria ................................................................ 30
8.1.3. Gastrointestinal Evaluation Criteria .............................................. 31
8.1.4. Rash/Hypersensitivity Evaluation Criteria ..................................... [ADDRESS_303097] to Follow Up ........................................................................................ 31
9.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 32
9.1. Efficacy Assessments ................................................................................. 32
9.2. Advers e Events ........................................................................................... 32
9.2.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................... 33
9.2.2. Method of Detecting AEs and SAEs ............................................. 33
9.2.3. Follow -up of AEs and SAEs ......................................................... 33
9.2.4. Regulatory Reporting Requirements for SAEs ............................. 34
9.2.5. Pregnancy ................................................................................... 34
9.3. Treatment of Overdose ............................................................................... 34
9.4. Safety Assessments ................................................................................... 35
9.4.1. Physical Examinations ................................................................ .35
9.4.2. Vital Signs .................................................................................... 35
9.4.3. Electrocardiograms ...................................................................... 35
9.4.4. Clinical Safety Laboratory Assessments ...................................... 35
9.5. Pharmacokinetics ....................................................................................... 36
9.5.1. Blood Sample Collection .............................................................. 36
9.5.2. Urine Sample Collection .............................................................. 36
9.5.3. Saliva Sample Collection ............................................................. 36
9.5.4. Sample Analysis .......................................................................... 36
9.6. Pharmacodynamics .................................................................................... 37
9.7. Genetics ..................................................................................................... 37
9.8. Biomarkers ................................................................................................ .37
9.9. Health Economics OR Medical Resou rce Utilization and Health 
Economics .................................................................................................. 37
10.STATISTICAL CONSIDER ATIONS ........................................................................ 37
10.1. Sample Size Determination ........................................................................ 37
10.2. Populations for Analyses ............................................................................ 38
10.3. Statistical Analyses ..................................................................................... 38
10.3.1. Pharmacokinetic Analyses ........................................................... 38
10.3.2. Safety Analyses ........................................................................... 39
10.3.3. Other Analyses ............................................................................ 40
10.3.4. Interim Analyses .......................................................................... 41
11.REFERENCES ....................................................................................................... 42
12.APPENDICES ........................................................................................................ 44
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 44
12.2. Appendix 2: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 46
12.3. Appendix 3: Study Governance Considerations .......................................... 50
12.4. Appendix 4: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 54
12.5. Appendix 5: Follow -up for Gastrointestinal Findings ................................... 56
12.6. Appendix 6: Clostridium Difficile Testing Procedure and Algorithm ............. 57
12.7. Appendix 7: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ....................................... 58
12.8. Appendix 8: Clinical Laboratory Tests ......................................................... 63
12.9. Appendix 9: Genetics .................................................................................. 65 2018N388749_00
2017N352027_00 CONFID ENTIA L
BTZ117352
512.10. Appendix 10: DMID Adult Toxicity Tables for AE Assessment .................... 66 2018N388749_00
2017N352027_00 CONFID ENTIA L
BTZ117352
61. SYNOPSIS
Protocol Title: A Phase I, Open -Label, Single -Dose, Two-Part Study  to Assess the 
Pharmacokinetics of Gepotidacin ([COMPANY_004]2140944) in Male and Female Adult Participants
with Vary ing Degrees of Hepatic Impairment and in Matched Control Participants with 
Normal Hepatic Function
Short Title: Pharmacokinetics Study  of Gepotidacin ([COMPANY_004]2140944) in Adult 
Participants with Vary ing Degrees of Hepatic Impairment and in Matched Con trol 
Participants with Normal Hepatic Function
Rationale:
In a previous absorption, distribution, metabolism, and excretion study  for gepotidacin, 
the mean recovery  of radioactivity  in urine and feces accounted for approximately  31.2% 
and 52.5%, respective ly, of [14C]-gepotidacin administered as a single oral dose. After 
oral administration, gepotidacin was eliminated mainly  as parent in urine, accounting for 
approximately  20% of the administered dose. Elimination via metabolism (urine plus 
feces) accounted for a total of 13% to 19% of the dose.
It is expected that potential patients in future gepotidacin Phase III studies may  have at 
least some degree of hepatic impairment. The results from this study  will enable the 
development of appropriate dosing recommendations in patients with impaired hepatic 
function.
Objectives and Endpoints:
Objectives Endpoints
Primary
 To compare the plasma pharmacokinetic 
(PK) parameters of a 1500 mg oral dose of 
gepotidacin in normal healthy participants to 
participants with m ild, moderate, and severe 
hepatic impairment Plasma gepotidacin AUC(0- ) and Cmax, 
as data permit
Secondary
 To assess the safety and tolerability of 
gepotidacin administered as a 1500 mg oral 
dose in normal healthy participants 
compared with participants with mild, 
moderate, and severe hepatic impairment 12-lead safety electrocardiogram (ECG)
readings, change from baseline in vital sign 
measurements (blood pressure and heart 
rate), monitoring of AEs, toxicity grading of 
clinical laboratory test results, a nd physical 
examinations
 To compare the secondary plasma PK 
parameters of a 1500 mg oral dose of 
gepotidacin in normal healthy participants 
with participants with mild, moderate, and 
severe hepatic impairment Plasma gepotidacin AUC(0- t), Tmax, tlag,
CL/F, Vz/F, z,andt1/2, as data permit 2018N388749_00
2017N352027_00 CONFID ENTIA L
BTZ117352
7Objectives Endpoints
 To compare the urine PK parameters of a 
1500 mg oral dose of gepotidacin in normal 
healthy participants with participants with 
mild, moderate, and severe hepatic 
impairment Urine primary PK endpoints include Ae 
total, f e%, and CLr of gepotidacin, as data 
permit. Urine secondary PK endpoints 
include Ae(t1 -t2), AUC(0 -12), AUC(0 -24), 
and AUC(0- 48) of gepotidacin, as data 
permit
Exploratory
 To evaluate the saliva PK parameters of a 
1500 mg oral dose of gepotidacin in norma l 
healthy participants compared with
participants with mild, moderate, and severe 
hepatic impairment Saliva primary PK endpoints include 
AUC(0 -) and Cmax of gepotidacin, as 
data permit. Saliva secondary PK 
endpoints include AUC(0 -t), Tmax, z, 
t1/2, CL/F, Vz/F, and saliva to unbound 
plasma AUC(0 -t) and AUC(0 -) ratios
(RAUC) of gepotidacin, as data permit
Overall Design:
This is a Phase I, nonrandomized, open -label, parallel -group, multi -center, two- part stud y 
that will evaluate the pharmacokinetics, saf ety, and tolerability of a single 1500 mg oral
dose of gepotidacin in participants with normal hepatic function and in participants with 
mild, moderate, and severe hepatic impairment . Healthy  participants with normal hepatic
function will be match ed to hep atically  impaired participants in terms of gender 
distribution, age (approximately  ±10 y ears), and body  mass index (approximately  ±20%).
At Screening, participants will be enrolled to the appropriate groups based on the 
classification as defined in the Foo d and Drug Administration Guidance for Industry , 
Pharmacokinetics in Patients with I mpaired Hepatic Function: Study  Design, Data 
Analy sis, and Impact on Dosing and Labeling [DHHS , 2003]. Participants with hepatic 
impairment will be cla ssified using the Child -Pugh sy stem.
This will be a two-part study , in which PK objectives must be achieved (observed mean 
values: area under the concentration -time curve [AUC] <48 ghr/mL  and maximum 
observed concentration [Cmax] <14 g/mL); and safet y and tolerability  will be reviewed 
before enrolling participants into the next part of the study . In Part 1, participants with 
moderate hepatic impairment and participants with normal hepatic function will be 
enrolled. Matching p articipants with normal hepat ic function in Part 1 (Group D) will be 
enrolled following the completion of all Day 3 assessments of the respective matched 
hepaticall y impaired participant .
In Part 2, participants with mild (optional) and severe hepatic impairment and 
participants with normal hepatic function will be enrolled concurrentl ybased on the PK, 
safet y, and tolerability data of Part 1.Participants with mild hepatic impairment may  be 
studied if there is a significant difference in pharmacokinetics between participants with 
mode rate hepatic impairment andparticipants with normal hepatic function . Participants 
with severe hepatic impairment will be studied in Part 2 provided that the PK objectives 
are achieved in Part 1 (observed mean values in participants with moderate impairme nt  2018N388749_00
2017N352027_00 CONFID ENTIA L
BTZ117352
8do not exceed the threshold: AUC <48ghr/mL and Cmax <14 g/mL). The dose may  
be adjusted for participants with severe hepatic impairment if either PK parameter is 
predicted to exceed the threshold. Based on emergent data from Part 1, matching 
partici pants with normal hepatic function in Part 2 (Group E) may  be enrolled (e.g., if a 
change in dose is needed or if the demographic data of the mild and/or severe hepatic 
impairment groups is not well matched to the moderate control data [Group D]).
For participants with normal hepatic function andparticipants with mild, moderate, and 
severe hepatic impairment: participants will participate in 1 treatment period and blood ,
urine, and saliva samples will be collected up to approximately  48 hours after dosing for 
PK analy sis of gepotidacin concentrations .
Number of Participant s:
For the target sample size of 8 evaluable participants each in mild, moderate ,and severe 
hepatic impairment groups, the maximum number of evaluable participants in this study  
is 48 (as suming 24 matching participants with normal hepatic function for the 
24hepaticall y impaired participants).
Due to the potential difficulty  in identify ing eligible participants with severe hepatic 
impairment, the sponsor may  stop the study  prior to full en rollment in Part [ADDRESS_303098] been 
enrolled.
Treatment Groups and Duration:
Participants will be screened within 30 day s prior to entry  to the clinic and will be 
assigned to a study  group based on the degree of hepatic impairment using the 
Child -Pugh classification sy stem :
Part 1:
Group B: Participants with moderate hepatic impairment (Child -Pugh score 7 to 9)
Group D: Participants with normal hepatic function
Preliminary  PK, safet y, and tolerability results from participants in Part 1 will be 
reviewed before enrolling participants into the next part of the study .
Part 2:
Group A: Participants with mild hepatic impairment (Child -Pugh score 5 to 6 )
(optional)
Group C: Participants with severe hepatic impairment (Child- Pugh score 10 to 15)
Group E: Participants with normal hepatic function (optional)
Participants in Parts 1 and 2 will en ter the clinic at Check -in (Day −1) before study  drug 
administration (Day  1). Participants will receive a single oral dose of stud y drug as 
follows: gepotidacin 1500 mg administered as 2 × [ADDRESS_303099]  2018N388749_00
2017N352027_00 CONFID ENTIA L
BTZ117352
9been completed, and will return to the clinic for a Follow- up Visit approximately  10 day s 
(±5 day s) after dose administration. The duration of the study  (from Screening to the 
Follow -up Visit) will be approximately  44 day s. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
102. SCHEDULE OF ACTIVITIES (SOA)
Table 1 Time and Events Table
Procedure1Screening 
(up to 30 days 
prior to Day -1)Check- inTreatment Period
(Days)Follow -up 
(10 [±5] days 
postdose) or 
Early TerminationNotes
–1 1 2 3
Confined to clinic X X X XParticipants will be admitted to the clinic on 
Day – 1 and will be discharged on Day 3. 
Confinement will be 4 days and 3 overnight 
stays
Informed consent X
Inclusion and exclusion criteria X XRecheck clinical status before enro llment 
and/or study drug administration
Demographics X
Complete physical examination including 
height and weightX
Abbreviated physical examination X X X
Medical history (includes substance 
usage and history of hepatic disease)XSubstances: drugs, alcohol, and caffeine. 
Participants with hepatic impairment should 
be on a stable regimen of chronic 
medications [ADDRESS_303100] and current medical conditions 
(including hepatic impairment medical 
history ,Child -Pugh score , and Clcr )XChild -Pugh as defined in the FDA Guidance 
for Industry: Pharmacokinetics in Patients 
with Impaired Hepatic Function
[DHHS 2003]
Pregnancy test X X XUrine(or serum ) pregnancy test (if 
WOCBP) , as appropriate (s ee Table 5)
FSH XEstradiol and FSH at Screening (for women 
ofnon-childbearing potential) , as 
appropriate (see Table 5 ) 
 
 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
11Procedure1Screening 
(up to 30 days 
prior to Day -1)Check- inTreatment Period
(Days)Follow -up 
(10 [±5] days 
postdose) or 
Early TerminationNotes
–[ADDRESS_303101] has otherwise been performed within 
3 months before study drug administration, 
testing at Screening is not required
Drug and alcohol screen X X SeeTable 5
Laboratory assessments (include liver 
chemistries)X X X XIncluding serum chemistry, hematology ,and 
urinalysis. Results from 24 hours after 
dosing should be available before discharge 
on Day 3
12-lead ECG X X X X X X S ee Table 2for timing of assessments
Vital signs X X X X X XRespi[INVESTIGATOR_249192] 2for timing of assessments
Genetic sample XInformed consent for optional substudies 
(e.g., genetics research) must be obtained 
before collecting a PGx sample .The PGx 
sample can be collected anytime, but 
Day−[ADDRESS_303102] different collecti on intervals
See Table 2for time points
Saliva collection for pharmacokinetics X X X See Table 2for time points
AE/SAE review X X ================== X
Concomita nt medication review X ================== X
AE = adverse event, Clcr = estimated creatinine clearance; ECG = electrocardiogram, FDA = Food and Drug Administration; FSH = follicle -stimulating hormone; HIV = human 
immunodeficiency virus; PGx = pharmacog enetic, SAE = serious AE; W OCBP =women of childbearing potential.
1 When coinciding with safety and/or pharmacokinetic assessments, electrocardiograms, vital signs, and pharmacokinetic blood co llections should be performed in said order. 
 
 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
12Table 2 Safety  and PK A ssessments
Procedure1Treatment Period
Time point (hours)
Predose 0 0.5 1 1.5 2 2.5 3 4 6 8 12 242 362 482
12-lead electrocardiogram X X X X X X X X X
Vital signs X X X X X X X X X
Study drug administration X
Blood collection for 
pharmacokineticsX X X X X X X X X X X X X X
Urine collection for 
pharmacokinetics (participants
with normal hepatic function)3X X X X X X X X X X
Urine collection for 
pharmacokinetics (participants
withhepatic impairment)4X X X X X X X
Saliva collection X X X X X X X X X X X X X X
1 When coinciding with safety and/or pharmacokinetic assessments, electrocardiograms, vital signs, and pharmacokinetic blood co llections should be performed in said order.
2 The 24-, 36-, and 48 -hour postdose time points correspond to time points on Day 2 and 3, respectively.
3 Urine collection intervals for participants with normal hepatic function (Group D and Group E, if applicable ) include 0 (pre -dose), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 
hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours.
4 Urine collection intervals for participants with hepatic impairment (Group A, Group B, and Group C ) include 0 hour (pre -dose), 0 to 6 hours, 6 to 12 hours, 12 to 24 hours, 24 to 36, 
and 36 to 48 hours.
The timing and number of planned study  assessments, including: safet y and pharmacokinetic assessments may  be altered during 
the course of the study  based on newl y available data (e.g., to obtain data closer to the time of peak plasma concentrations) to 
ensure appropriate monitoring.
Any changes in the timing or addition of time points for any  planned stud y assessments must be documented and approved by 
[CONTACT_249220] y team member and then archived in the spon sor and site study  files, but will not constitute a protocol 
amendment. The IRB/IEC will be informed of any  safet y issues that require alteration of the safet y monitoring scheme or 
amendment of the ICF. 
 
 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
133. INTRODUCTION
Gepotidacin is a novel triazaacenaphth ylene bacterial topoisomerase inhibitor, which 
inhibits bacterial DNA replication and has in vitro activity  against susceptible and 
drug-resistant pathogens associated with a range of conventional and biothreat infections.
Gepotidacin has demonstrated in vitroactivity  and in vivo efficacy  against conventional 
and biothreat pathogens, including isolates resistant to existing classes of antimicrobials. 
Gepotidacin selectively inhibits bacterial DNA gyrase and topoisomerase IV by  a unique 
mechanism, which is not utilized by  [CONTACT_249221]. 
Structural data with a t ype II topoisomerase, DNA gyrase, reveals the novel binding 
mode of the class and distinguishes it from the binding mode of the quinolone 
antibacterials [Bax, 2010]. As a c onsequence of its novel mode of action, gepotidacin is 
active in vitro against target pathogens carry ing resistance determinants to established 
antibacterials, including fluoroquinolones.
3.1. Stud y Rationale
In a previous absorption, distribution, metabolism, and excretion (ADME) study  for 
gepotidacin ( see [COMPANY_004] Document Number 2014N189951_00 Study  ID BTZ115774), the 
mean recovery  of radioactivity  in urine and feces accounted for approximately  31.2% and 
52.5%, respectively , of [14C]-gepotidacin adm inistered as a single oraldose. After oral 
administration, gepotidacin was eliminated mainly as parent in urine, accounting for 
approximately  20% of the administered dose. Elimination via metabolism (u rine plus 
feces) accounted for a total of 13% to 19% of the dose.
It is expected that potential patients in future gepotidacin Phase III studies may  have at 
least some degree of hepatic impairment. The results from this study  will enable the 
development of appropriate dosing recommendations in patients with impaired hepatic
function.
3.2. Background
Gepotidacin has demonstrated clinical efficacy  in a Phase II study  for acute bacterial skin 
and skin structure infections, and in a Phase II study  for gonorrhea.
3.3. Benefit/Risk A ssessment
Summaries of findings from both clinical and nonclinical studies conducted with 
gepotidacin can be found in the Investigator’s Brochure. The following section outlines 
the risk assessment and mitigation strategy  for this protocol. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
143.3.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) Gepotidacin
Gastrointestinal (GI) Effects Lower GI effects (soft stools, flatulence, and diarrhoea) are 
the most com mon GI- associated adverse events (AEs) 
reported in human participants dosed with gepotidacin.
In the Phase I studies, out of approximately [ADDRESS_303103] received gepotidacin, Clostridium
difficile has been reported in 8 participants .Exclusion criterion and close monitoring of clinical 
parameters and AEs will be conducted to mitigate and 
assess GI effects.
Patients with significant GI symptoms will obtain the 
appropriate work -up (Appendix 5).
Participant evaluation criteria: Participants experiencing 
Grade 3 or Grade 4 AEs will be followed as appropriate 
until resolution of the AE (see Section 8.1.3 ).
Cardiovascular Effects
Reversible increase in QT prolongation and a mild 
increase in heart rate in human participants.In Study BTZ115775 (see [COMPANY_004] Document Number 
2015N227098_00 Study ID BTZ115775 ), the infusion of 
gepotidacin at a dose of [ADDRESS_303104] of approximately 
6bpm to 10 bpm and a QT prolongation, measured as 
∆∆QTcF, of 12 msec to 22 msec. The QT prolongation 
evolved during the infusion and was quickly reversed over 
2 hours after the end of the infusion. Blood pressure
observations were within normal ranges. Exclusion criteria, close monitoring of clinical parameters, 
and AEs will be conducted and stoppi[INVESTIGATOR_249193].
Note: Participants with baseline QTcF in terval >450 msec 
(participant with normal hepatic function) or >480 msec 
(hepatically impaired participant) will be excluded.
Participant monitoring criteria: Participants experiencing a 
QTcB and/or QTcF >500 msec and/or a change from 
baseline in QTc >60 msec (see Section 8.1.2 ). 
 
 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
15Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Acetylcholinesterase (AChE) Inhibition
In a mass spectrometry model performed with gepotidacin, 
AChE was inhibited with a concentration of inhibitor where 
the response (or binding) was reduced by [CONTACT_2016] (inhibitory 
concentration) of approximately 5 µg/mL (7.5 µg/mL of 
total drug concentration).At higher doses, some participants have experienced 
effects consistent with increased cholinergic tone, including 
central nervous system and GI effects ( increased
salivation, slurred speech, blurred vision, dizziness, 
light-headedness, and GI upset) . These effects appear to 
be related to Cmax and are significantly attenuated when 
Cmax is below 14 g/mL.Coadministration of anticholinergics and administration in 
participants with certain concomitant conditions will be 
excluded.
Close monitoring of clinical parameters and AEs will be 
conducted to assess effects potentially related to AChE 
inhibition. The Cmax is expected to be below 14 g/mL in 
this study.
Rash/Hype rsensitivity A fine, mild, generalized pruritic macular skin rash was 
seen in 3 of 8 participants following 10 days of dosing 
1500 mg 3 times daily (see [COMPANY_004] Document Number 
2014N198291_00 Study ID BTZ115198).
Rash was reported as an AE for 4 of 122 participants (3%) 
and consisted of mild, related urticaria; moderate, related 
rash maculopapular; mild, related rash; mild, related 
urticaria; and mild, not related arthropod bite (see [COMPANY_004] 
Document Number 2015N243789_00 Study ID 
BTZ116704).
There has been no other evidence of hypersensitivity in 
human participants to date.Exclusion criterion :
History of sensitivity to any of the study drugs, components 
thereof, or a histor y of drug or other allergy that, in the 
opi[INVESTIGATOR_249194], contraindicates their participation.
Participant monitoring:
Participants will be monitored closely for cutaneous effects 
throughout the study, and spe cialist advice will be sought 
as needed to evaluate any clinically significant finding.
Participant evaluation criteria :
Grade 3 or higher rash or Grade 2 rash with evidence of 
systemic involvement (see Section 8.1.4 ). 
 
 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 [ADDRESS_303105] clinical benefit to study  participants. Participation in this study  will contribute to 
the process of developi[INVESTIGATOR_249195].
3.3.3. Overall Benefit:Risk Conclusion
The risk of adverse events (AEs) is minimized for the populations being investigated in 
the proposed stud y by [CONTACT_249222] ; the 
relativel y short duration of study drug exposure; and the extent of safet y monitoring 
incorporated into the study .
4. OBJECTIVES A ND ENDPO INTS
Objectives Endpoints
Primary
 To compare the plasm a pharmacokinetic 
(PK)parameters of a 1500 mg oral dose of 
gepotidac in in normal healthy participants to
participants with mild, moderate, and severe 
hepatic impairment Plasma gep otidacin AUC(0 -) and Cmax, 
as data permit
Secondary
 To assess the safety and tolerability of 
gepotidacin administered as a 1500 mg oral 
dose in normal healthy participants
compared with participants with mild, 
moderate, and severe hepatic impairment 12-lead safety electrocardiogram (ECG)
readings, change from baseline in vital sign 
measurements (blood pressure and heart 
rate), monitoring of AEs, toxicity grading of 
clinical laboratory test results, and physical 
examinations
 To compare the secondary plasma PK 
parameters of a 1500 mg oral dose of 
gepotidacin in normal healthy participants
withparticipants with mild, moderate, and 
severe hepatic impairment Plasma gepotidacin AUC(0- t), Tmax, tlag, 
CL/F, Vz/F, z,andt1/2, as data permit
 To compare the urine PK parameters of a 
1500 mg oral dose of gepotidacin in normal 
healthy participants with participants with 
mild, moderate, and severe hepatic 
impairment Urine primary PK endpoints include Ae 
total, fe%, and CLr of gepotidacin, as data 
permit. Urine secondary PK endpoints 
include Ae(t1 -t2), AUC(0 -12), AUC(0 -24), 
and AUC(0- 48) of gepotidacin, as data 
permit 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
17Objectives Endpoints
Exploratory
 To evaluate the saliva PK parameters of a 
1500 mg oral dose of gepotidacin in normal 
healthy participants compare dwith
participants with mild, moderate, and severe 
hepatic impairment Saliva primary PK endpoints in clude 
AUC(0 -) and Cmax of gepotidacin, as 
data permit. Saliva secondary PK 
endpoints include AUC(0 -t), Tmax, z, 
t1/2, CL/F, Vz/F, and saliva to unbound
plasma AUC(0 -t) and AUC(0 -)ratios 
(RAUC) of gepotidacin, as data permit
5. STUDY DESIGN
5.1. Overall Design
This is a Phase I, nonrandomized, open -label, parallel -group, multi -center, two- part stud y 
that will evaluate the pharmacokinetics, safet y, and tolerability of a single 1500 mg oral
dose of gepotidacin in participants with normal hepatic function and in p articipants with 
mild, moderate, and severe hepatic impairment . Healthy  participants with normal hepatic
function will be match ed to hepatically  impaired participants in terms of gender 
distribution, age (approximately  ±10 y ears), and body  mass index ( BMI; approximately  
±20%).
At Screening, participants will be enrolled to the appropriate groups based on the 
classification as defined in the Food and Drug Administration (FDA) Guidance for 
Industry , Pharmacokinetics in Patients with I mpaired Hepatic Function: Study  Design, 
Data Anal ysis, and Impact on Dosing and Labeling [DHHS , 2003 ]. Participants with 
hepatic impairment will be classified using the Child -Pugh sy stem . For mor e details see 
Section 7.3.
This will be a two-part study , in which PK objectives must achieved (observed mean 
values: area under the concentration -time curve [AUC] <48 ghr/mL  and maximum 
observed concentration [Cmax] <14 g/mL); and safety and tolerability will be reviewed 
before enrolling participants into the next part of the study . In Part 1, participants with 
moderate hepatic impairment and participants with normal hepatic function will be 
enrolled. Matching participants with normal hepatic function in Part 1 (Group D) will be 
enrolled following the completion of all Day  3assessments of the respective matched 
hepaticall y impair ed participant (see Section 7.3).
In Part 2, participants with mild (optional) and severe hepatic impairment and 
participants with normal hepatic function will be enrolled concurrentl y based on the PK, 
safet y, and tolerability data of Part 1.Participants with mild hepatic impairment may  be 
studied if there is a significant difference in pharmacokinetics between participants with 
modera te hepatic impairment andparticipants with normal hepatic function . Participants
with severe hepatic impairment will be studied in Part 2 provided that the PK objectives
are achieved in Part 1 (observed mean values in participants with moderate impairment
do not exceed the threshold: AUC <48ghr/mL and Cmax <14 g/mL) . The dose may  
be adjusted for participants with severe hepatic impairment if either PK parameter is 
predicted to exceed the threshold . Based on emergent data from Part 1, matching  2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
18participa nts with normal hepatic function in Part 2 (Group E) may be enrolled (e.g., if a 
change in dose is needed or if the demographic data of the mild and/or severe hepatic 
impairment groups is not well matched to the moderate control data [Group D]) (see 
Sectio n 7.3).
Due to the potential difficulty  in identify ing eligible participants with severe hepatic 
impairment, the sponsor may  stop the study  prior to full enrol lment in Part [ADDRESS_303106] been 
enrolled. See the stud y schematic in Figure 1for more details.
For participants with normal hepatic function andparticipants with mild, moderate, and 
severe hepatic impair ment: participants will participate in 1 treatment period and blood ,
urine, and saliva samples will be collected for PK anal ysis of gepotidacin concentrations 
according to the 
Schedule of Activities ( SoA;Section 2). Blood, uri ne, a nd saliva 
samples will be collected up to approximately  48hours after dosing.
Figure 1 BTZ1 117352 Study  Schematic
PK = pharmacokinetic
1 Based on emergent data from Part 1, participants with mild hepatic impairment (Group A ) may not be enrolled in 
Part 2 if there is not a signifi cant difference between participants with moderate hepatic impairment and 
participants with normal hepatic function. 
2 If AUC and/or Cmax are predicted to exceed the thres hold, the dose may be adjusted for participants with severe 
hepatic impairment (Group C) . Due to the potential difficulty in identifying eligible participants with severe hepatic 
impairment, the sponsor may stop the study prior to full enrollment in Part [ADDRESS_303107] been enrolled.
3 Based on emergent data from Part 1, matching participants with normal hepatic function in Part 2 (Group E)may 
be enrolled (e.g., if a change in dose is needed or if the dem ographic data of the mild and/or severe hepatic 
impairment groups is not well matched to the moderate control data [Group D]) .Part 1
Group B : Participant s with mode rate hepatic impairment
Group D : Participants with normal hepatic function
PK requirements to continue to Part 2
Observed Mean Values:
AUC <48 ghr/mL
Cmax <14 g/mL
(Based on emerging d ata, and/or data that are not expected to 
exceed these requirements in participants with severe hepatic 
impairment or may require dose adjustment, participants in 
Part 2 will be enrolled.)
Part 2
Group A: Participants with mild hepatic impairment (optional)1
Group C : Participants with severe hepatic impairment2
Group E : Participants with normal hepatic function (optional)3 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
195.2. Number of Participants
For the target sample size of 8 evaluable participants each in mild, moderate and severe 
hepatic impairment groups, the maximum the number of evaluable participants in this 
study  is 48 (assuming 24 matching participants with nor mal hepatic function for the 
24hepaticall y impaired participants).
Due to the potential difficulty in identif ying eligible participants with severe hepatic 
impairment, the sponsor may  stop the study  prior to full enrol lment in Part [ADDRESS_303108] completed the study  if he/she has compl eted all 
phases of the stud y including the Follow -up Visit.
The end of the stud y is defined as the da te of the last visit of the last participant in the 
study .
5.4. Scientific Rationale for Study  Design
This study  design is commonly  used when evaluating the pha rmacokinetics of a drug 
entity  in participants with impaired hepatic function. I t is based on recommendations 
given in the FDA Guidance for Industry ,Pharmacokinetics in Patients with Impaired 
Hepatic Function: Study  Design, Data Anal ysis, and I mpact on Do sing and L abeling 
[DHHS , 2003 ].
Gepotidacin exhibits linear and time -independent pharmacokinetics, which indicates a 
single -dose study  is adequate to achieve study  objectives.
In the human ADME study  (see report of s tudy BTZ115774) , total recovery  of 
radioactivity  was approximately  84% (31.2% in urine and 52.5% in fec es) after oral 
administration. Radioactivity  was eliminated in higher proportions in feces for oral doses, 
suggesting hepatic impairment could affect clearance of the paren t compound. The 
absolute oral bioavailability  was approximately  44%.
5.5. Dose Justification
The oxidative metabolism of gepotidacin is mediated primaril y by c ytochrome P450 
enzy me 3A4 (CYP3A4). In a clinical drug- drug interaction study  when itraconazole 
(inhib itor of both p-glycoprotein and CYP3A4) was co-administered with gepotidacin, a 
weak drug- drug interaction (40% increase in Cmax and 50% increase in AUC[0- ∞]) was 
observed (see [COMPANY_004] Document Number 2014N199850_00 Study  ID BTZ117 349). 
Therefore, the mean Cmax and AUC following a single oral dose of gepotidacin 1500 mg 
are not expected to exceed those observed in healthy  adult participants who received  2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
20gepotidacin 3000 mg(see [COMPANY_004] Document Number 2012N137722_00
Study IDBTZ114595 ).
6. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
6.1. Inclusion Criteria
Participants are eligible to be included i n the study  only  if all of the following criteria 
apply :
Age
1.Participant must be [ADDRESS_303109] be in clinically  stable health as determined by  [CONTACT_249223] , clinical laboratory  results (seru m chemistry , 
hematology , urinaly sis, and serology ), vital sign measurements, 12- lead 
electrocardiogram ( ECG )results, and ph ysical examination findings.
3.Hepaticall y impaired participan tsmust have chronic (>6 months), stable (no acute 
epi[INVESTIGATOR_249196] 1 month prior to screening due to 
deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due 
to any  etiolog y. Participants must also remain stable throughout the Screening 
period.
4.Hepaticall y impaired participants will be classified using the Child- Pugh 
classification s ystem (see Table 3) . Participants must have a Child -Pugh score of 5 to 
6 (mild hepatic impairment), 7 to 9 (moderate hepatic impairment), or 10 to 
15(severe hepatic impairment) with known medical history  of liver disease (with or 
without a known history  of alcohol abuse) and previous confirmation of liver 
cirrhosis by  [CONTACT_249224] (including laparoscopy , 
computed tomograph yscan, magnetic resonance imaging , or ultrasonography ) 
associated with unambiguous medical history .If imaging stud y or biops y is not 
available, then the participant s hould have one of the following: 
i.Physical findings such as hepatomegal y, ascites, palmar ery thema, spi[INVESTIGATOR_249197], abdominal venous collaterals, gy necomastia, or other phy sical 
manifestations of hepatic disease
OR
ii.Laboratory  findings: alanine aminotransferase ( ALT )or aspartate 
aminotransferase elevation ( >upper limit of normal [ULN]), alkaline 
phosphatase, or total bilirubin, or international normalized ratio (INR) elevation 
(>ULN ) or an albumin value that is below the lower limit of normal laboratory  
reference range. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 [ADDRESS_303110] platelet counts 30,000 × 109/L of 
blood and have not had any  major ble eding epi[INVESTIGATOR_249198] 6 months.
Weight
7.Body weight 45kgand BMI within the range 18.5 to 40 kg/m2(inclusive).
Sex
8.Male or female
a. Male participants:
A male participant must agree to use contraception as detailed in Appendix 2of this 
protocol from Day -1 until completion of the Follow- up Visit .
b.Female participants:
Afemale participant is eligible to participate if she is not pregnant (see Appendix 2),
not breastfeeding, and at least one of the followin g conditions applies:
i.Not a woman of childbearing potential (WOCBP) as defined in Appendix 2
OR
ii.A WOCBP who agrees to follow the contraceptive guidance in Appendix 2
from 30 day sprior to study  drug administration and until completion of the 
Follow -up Visit .
Informed Consent
9. Capable of giving signed informed consent as described in Appendix 3which
includes compliance with the requirements and restrictions listed in the informed 
consent form (I CF) and in this protocol.
6.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1. Participant has a clinically significant abnormality in past medical history  or at the 
Screening ph ysical exa mination (excluding hepatic insufficiency  and other related 
medical conditions within the hepaticall y impaired populations which should be 
stable for at least 1 month before study  drug administration ) that in the investigator’s 
opi[INVESTIGATOR_249199] . This includes, but is not limited to, history  or current significant cardiac, renal, 
neurologic, gastrointestinal, respi[INVESTIGATOR_696] , hematologic, or immunologic disease. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
222.Participant has an y surgica l or medical condition (active or chronic) that may  
interfere with drug absorption, distribution, metabolism, or excretion of the study  
drug, or an y other condition that may place the participant at risk, in the opi[INVESTIGATOR_13046].
3.Female particip ant has a positive pregnancy  test result or is lactating at Screening or 
upon admission to the clinic.
4.Participant has used a s ystemic antibiotic within 7days of Screening .
5.Participant has a confirmed history  of Clostridium difficile infection or a positi ve 
C.difficile toxin test within 2 months before Screening .
6.Participant has a history  of drug and/or alcohol abuse within 6 months before 
Screening, as determined by  [CONTACT_093], or participant has a positive drug 
screen at Screening or upon admission to the clinic. For participants with hepatic 
impairment, and a positive drug screen result related to the use of prescription 
medications is allowed per investigator review and approval, and 
tetrah ydrocannabinol use is allowed per investigator review and approval.
7.History  of sensitivity  to any  of the stud y drugs, components thereof, or a history  of 
drug or other allergy  that, in the opi[INVESTIGATOR_249200], 
contraindicates their participation.
8.History  of sensitivity  to heparin o r heparin -induced thrombocy topenia (if the clinic 
uses heparin to maintain intravenous cannula patency ).
Prior/Concomitant Therapy
9.Participant has used medications known to affect the elimination of serum creatinine 
(e.g., trimethoprim or cimetidine) or co mpetitors of renal tubular secretion 
(e.g., probenecid) within [ADDRESS_303111] abstain from taking prescription or nonprescription drugs 
(including vitamins and dietary  or herbal supplements), unless specified in 
Section 7.7.1 , within 7 days (or 14 day s if the drug is a potential strong enzy me 
inducer) or 5 half -lives (whichever is longer) prior to study  drug administration until 
completion of the Follow -Up Visit, unless, in the opi[INVESTIGATOR_249201], the medication will not interfere with the study .Any exceptions (including 
participants with hepatic impairment that will be on medications during the study ) 
will be discussed with the sponsor or medical monitor on a case- by-case basis and
the reasons will be documented.
Prior/Concurrent Clinical Study Experience
11.Previous exposure to gepotidacin within [ADDRESS_303112] within the following time period prior to study  drug administration in the 
current stud y: [ADDRESS_303113] (whichever is longer). 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 [ADDRESS_303114] result at Screening or within 3 months prior to 
study  drug administration .Participant with hepatic impairment has e vidence o f 
recent, acute infectio n with hepatitis B and/or h epatitis C within preceding 6 months. 
Hepaticall y impaired participants with chronic h epatitis B or C (duration >6 months) 
are eligible for enrolment.
14.A positive test for human immunodeficiency  virus antibody .
15.Participant must be able to abstain from alcohol and limit use of nicotine and/or 
nicotine -containing products (up to 5 cigarettes/day  is acceptable for participants 
with hepatic impairment ) for [ADDRESS_303115] is not exclusionary for 
participants with hepatic impairment.
16.Participant has clinicall y significant abnormal findings in serum chemistry , 
hematology , or urinal ysis results obtained at Screening or Day  –1, other than those 
associated with underl ying hepatic conditions or other stable medical conditions 
consistent with the disease process in participants with hepatic impairment .
17.Participant with normal hepatic function has a baseline corrected QT interval using 
the Frid ericia formula (QTcF) of >450 milliseconds (msec) and participant with 
hepatic impairment has a baseline QTcF of >480 msec.
Other Exclusions
18.Donation of blood in excess of 500 mL  within 12 weeks prior to dosing or 
participation in the study  would result in donation of blood or blood products in 
excess of 500 mL  within a 56 -day period.
19.Participant is unable to comply with all study  procedures, in the opi[INVESTIGATOR_1070].
20.The participant should not participate in the study, in the opi[INVESTIGATOR_249202].
Supplemental Exclusion Criteria for Hepatically Impaired Participants
21.Participants with a pre -existing condition (except hepatic impairment) interfering 
with normal GIanatom y or motility  that could interfere with the absorption, 
metabolism, and/or excretion of the study  drugs. Participants with a history  of 
inflammatory  bowel disease should be excluded. Participants with a history of 
pepticulceration or pancreatitis within the preceding 6 months of screening should be 
excluded.
22. Particip antswith any  previous GIsurgery  (except appendectomy  or gall bladder 
removal >3 months prior to Screening ) may  be enrolled in this study  only if, in the 
opi[INVESTIGATOR_2511] i nvestigator and the medical monitor, it is not expected to interfere 
with the study  procedures or to pose an additional safet y risk to the participant . 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
2423.Participants receiving lactulose who are medicall y unable to halt lactulose 
administration from 8 h ours before dosing with study  drug to 4 hours after dosing 
with study  drug.
24.Participants with clinically active severe encephalopathy  (grade 3 or 4 as defined in 
Table 3) as judged b y the investigator or significant c entral nervous s ystem disease 
(e.g., dementia or seizures) which the investigator consi ders will interfere with the 
informed consent, conduct, completion, or results of this trial or constitutes an 
unacceptable risk to the participant .Participants with a prior history  of severe 
encephalopath y who are currentl y treated for this condition wil
l receive the 
appropriate score for encephalopath y.
25.Participants with estimated creatinine clearance (Clcr) 50 mL /min (calculated by  
[CONTACT_16424] -Gault Formula ). If the result calculated b y Cockcroft -Gault is between 
40and 50 mL/min, then the site may  complete a 24 -hour urine collection to more 
specificall y calculate the Clcr. A Clcr value  50mL/min via [ADDRESS_303116] no t been adequatel y treated with medication and/or surgical 
procedures.
27.Participants with electrolyte imbalance whose serum sodium levels are 
125mmol/L ; potassium levels are  2.5 mmol/ L; orcalcium levels are
6.1mmol/L .
28.Presence of hepatopulmonary  or hep atorenal sy ndrome.
29.Primary  cholestatic liver diseases.
30. H istory  of liver transplantation or participants in the severe hepatic impairment 
group that are expecting a liver transplant during the study  participation period.
31.Participants with signs of active ba cterial infection (including active spontaneous 
bacterial peritonitis).
32.Participants with transjugular intrahepatic portos ystemic shunt placement within the 
past 3 months.
33.Participants with unstable cardiac function or participants with hy pertension whose 
blood pressure that is not well controlled (based on the investigator’s discretion).
34.Diabetic participants whose diabetes that is not controlled (based on the 
investigator’ s discretion).
6.3. Lifest yle Restrictions
6.3.1. Meals and Dietary  Restrictions
Participants wi ll fast (no food or drink except water) for approximately  [ADDRESS_303117] m eals will be provided during the study  treatment period at times that 
do not interfere with study procedures . 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
25Refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit 
juice, pomelos, exotic citrus fruits, grapefruit hy brids, or fruit juices from 7 days 
before the start of dosing until after collection of the final PK s ample .
6.3.2. Caffeine, A lcohol, and Tobacco
Participants will abstain from ingesting caffeine -or xanthine -containing products 
(e.g., coffee, tea, cola drinks, and c hocolate) for 24hours before the start of dosing 
until after collection of the final PK sample.
Participants will abstain from alcohol for 24 hours before the start of dosing until 
after collection of the final PK sample.
Participants will be instructed to limit use of nicotine and/or nicotine -containing 
products for 24 hours before the start of dosing until after collection of the final PK 
sample. Up to 5cigarettes/day  is acceptable.
6.3.3. Activity
Participants will abstain from strenuous exercise fo r 48 hours before ea ch blood
collection for clinical laboratory  tests. Participants may  participate in light 
recreational activities during studies ( e.g., watching television, reading).
6.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subse quentl y entered in the stud y. A minima l set of screen failure information 
is required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publis hing requirements and to 
respond to queries from regulatory  authorities. Minimal information includes 
demograph y, screen failure details, eligibility  criteria, and an y serious adverse events 
(SAEs ).
Individuals who do not meet the criteria for participatio n in this study  (screen failure) 
may be rescreened. Rescreened participants should be assigned the same participant 
number as for the initial screening.
For eligibility  purposes, clinical laboratory evaluations or vital sign measurements may 
be repeated onceifanabnormal result is observed at the initial reading. Moreover, 
12-lead ECG abnormalities may need to be confirmed by  [CONTACT_249225]. I n the 
event that the participation in the study  is delay ed and some screening procedures had 
been performed outside the prescribed screening window, outdated screening procedures 
can be repeated.
For inclusion and Child -Pugh categorization, clinical laboratory  results that are deemed 
inconsistent with the usual stage of hepatic impairment may  be repeated.
Parti cipants who do not qualify  based on a reversible medical condition or mild 
inter-current illness may  be re -evaluated after further testing/examination or rescreened 
after the condition has resolved. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
267. TREATMENTS
Study  treatment is defined as an y investigatio nal treatment(s), marketed product(s), 
placebo, or medical device (s)intended to be administered to a study  participant according 
to the study  protocol.
7.1. Treatments A dministered
Study treatment n ame: Gepotidacin
Formulation description: Immediate -release t ablets containing gepotidacin (free 
base) an inactive formulation excipi[INVESTIGATOR_249203]: Tablet
Unit dose strength/
Dosage level :750mg/
1500 mg (2 × 750 mg)
Route of a dministration Oral
Dosing instructions: Dose with 240 mL of water in the f ed state (within 
30minutes after a standard breakfast) . Up to additional 
[ADDRESS_303118] in swallowing 
tablets
Physical description: A capsule -shape, white film -coated tablet with no 
identifying markings
Manufacturer /
Source of p rocurement:GlaxoSmithKline
7.2. Dose Modification
Based on emerging data from Part 1, t he dose may be reduced for participants with severe 
hepatic impairment if either PK parameter is predicted to exceed the threshold
(AUC <48ghr/mL  and Cmax <14g/mL ).
7.3. Method of Treatment A ssignment
This will be a nonrandomized ,open -label study . At Screening, participants will be 
assigned to a study  group based on the degree of hepatic impairment using the 
Child -Pugh classification sy stem as shown in Table 3. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
27Table 3 Child -Pugh Classification System
FindingPoints Scored for Each Observed Finding1
1 2 3
Encephalopathy grade2 None 1 or 2 3 or 4
or
Participant receiving 
medication(s) to prevent 
encephalopathy
Ascites Absent Slight Moderate
or
Participant receiving 
medication(s) to control 
ascites
Serum bilirubin (mg/dL) <2 2 to 3 >3
Serum albumin (g/dL) >3.5 2.8 to 3.5 <2.8
Prothrombin time (seconds prolonged)
Or
Prothrombin time INR<4
<1.74 to 6
1.7 to 2.3>6
>2.3
INR = international normalized ratio.
1 For each category ( encephalopathy grade, ascites, serum bilirubin, serum albumin, and prothrombin time or 
prothrombin time INR), points will be assigned based on the participant’s condition and the criterion met. The 
Child -Pugh class will be assigned based on the sum of these points as follows: 
Child -Pugh C lass A ( mild hepatic impairment ): 5 to 6 points
Child -Pugh C lass B ( moderate hepatic impairment ): 7to 9 points
Child -Pugh C lass C ( severe hepatic impairment ):10 to 15 points
2 Grade 0: normal consciousness, personality, neurological examination, electroencephalogram
Grade 1: restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cycles per second waves
Grade 2: lethargic, time -disoriente d, inappropriate behavior , asterixis, ataxia, slow triphasic waves
Grade 3: somnolent, stuporous, place -disoriented, hyperactive reflexes, rigidity, slower waves
Grade 4: unarousable coma, no personality/behavior, decerebrate, slow 2 -3 cycles per second delta activity
In Part 1, participants with moderate hepatic impairment (Group B) will be enrolled as 
they become eligible for the study  and receive their allocated participant numbers in the 
order in which they  are enrolled. Healthy  participants with normal hepatic function 
(Group D ) will be matched to the participants with moderate hepatic impairment in terms 
of gender distribution, age (±10 years), and BMI (±20% )and will be enrolled following 
the completion of all Day 3 assessments of the respective match ed hepatically  impaired 
participant.
In Part 2, participants with mild (optional) and severe he patic impairment (Groups A 
andC, respectivel y) will be enrolled concurrently  as they  become eligible for the study  
and receive their allocated participant numbe rs in the order in which they  are enrolled 
within their respective groups. Based on emergent data from Part 1, healthy participants 
with normal hepatic function in Part 2 (Group E) may be enrolled (e.g., if a change in 
dose is needed [see Section 7.2] or if the demographic data [gender, age, and BMI ] of the 
mild and/or severe hepatic impairment groups is not well matche d to the moderate 
control data [ Group D ]). Enrollment of health y participants with normal hepatic function 
in Part 2 will be performed in the same manner as Part 1. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
28Participants will be given a participant number that will be a unique identifier. Once a 
participant number has been assigned, the number will not be reused even if the 
participant withd raws from the study  before receiving gepotidacin.
7.4. Blinding
This will be an open -label study .
7.5. Preparation/Handling/Storage/A ccountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for al l study  treatment received and any  discrepancies 
are reported and resolved before use of the stud y treatment.
2.Only  participants enrolled in the study  may  receive study  treatment and only  
authorized site staff may  supply  or administer study  treatment. All s tudy treatments 
must be stored in a secure, environmentall y controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.
3.The investigator, institut ion, or the head of the medical institution (where applicable) 
is responsible for stud y treatment accountability, reconciliation, and record 
maintenance ( i.e.,receipt, reconciliation, and final disposition records).
4. Further guidance and information for th e final disposition of unused study  treatment 
are provided in the Study Reference Manual (SRM) .
5.Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .
6.A Material Safety Data S heet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
7.6. Treatment Compliance
When the individual dose for a participant is prepared from a bulk supply , the 
preparation of the dose will be confirmed b y a second member of the clinic staff. 
When participants are dosed at the clinic , they  will receive study treatment directly  
from the investigato r or designee, under medical supervision. The date and time of 
each dose administered in the clinic will be recorded in the source documents. The 
dose of study  treatment and study  participant identification will be confirmed at the 
time of dosi ng by a memb er of the clinic staff other than the person administering the 
study  treatment . Clinic personnel will examine each participant’s mouth to ensure 
that the study  treatment was ingested.
7.7. Concomitant Therapy
Any medication or vaccine (including over -the-counte r or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrollment or receives during the stud y must be recorded along with: 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
29reason for use
dates of administration including start and end dates
dosage information including dose and frequency
The medical m onitor should be contact[CONTACT_43205] y questions regarding 
concomitant or prior therapy .
7.7.1. Permitted Therapy
In health y participants with normal hepatic function, a cetaminophen at doses of 
2grams/ dayis permitted for use an y time during the study . Other concomitant 
medication may  be considered on a case -by-case basis by  [CONTACT_249226] m onitor.
Participants with h epatic impairment may  be taking medications whic h, in the opi[INVESTIGATOR_13046], are believed to be therapeutic, and these medications should not interfere 
with the conduct of the study . Participants with hepatic impairment should be on stable 
regimen of chronic medications for at least [ADDRESS_303119] abstain from taking prescription or nonprescrip tion drugs (including 
vitamins and dietary  or herbal supplements), unless specified in Section 7.7.1 ,within 
7days (or 14 day s if the drug is a potential enzy me inducer) or 5 half -lives (whichever is 
longer) prior to study  drug administration until completion of the Follow -Up Visit, 
unless, in the o pi[INVESTIGATOR_249204] , the medication wil l not interfere with 
the study .
Participants with hepatic impairment are prohibited from receiving lactulose from 8 hours 
before dosing with study  drug until 4 hours after dosing with study  drug.
Due to the potential for acet ylcholinesterase inhibition with gepotidacin, the following 
medications are prohibited:
Succiny lcholine or other depolarizing muscle relaxants.
Acet ylcholinest erase inhibitors as required for m yasthenia gravis including 
edrophonium, py ridostigmine, neostigmine, etc.
7.8. Treatment after the End of the Study
Participants will not receive an y additional treatment from [COMPANY_004] after completion of the 
study  because onl y heal thy participants andparticipants with mild, moderate, and severe 
hepatic impairment are eligible for stud y participation. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 [ADDRESS_303120]-study  care of the participant ’s medical condition, whether or not [COMPANY_004] is providing 
specific post -study  treatment.
8. DISCONTINUA TION CRIT ERIA
8.1. Discontinuation of Study  Treatment
8.1.1. Liver Chemistry Evaluation Criteria
Liver chemistry stoppi[INVESTIGATOR_249205] .
Although stoppi[INVESTIGATOR_249206], if participants are found to have values consistent with 
usual stoppi[INVESTIGATOR_128007], it is appropriate to institute evaluation and monitoring criteria 
according to standard [COMPANY_004] criteria. Therefore, liver function tests should be evaluated 
according to stoppi[INVESTIGATOR_249207].
The following liver chemistry  evaluation criterion will be applied for healthy 
participants:
ALT 3 ×ULN
Liver s afety  required a ctions and follow -up assessments can be found in Appendix 4.
8.1.2. QTc Evaluation Criteria
The same QT correction formula must be used for each individual participant to 
determine eligibility  for and discontinuation from the study . This formula may  not be 
changed or substituted once the participant has been enrolled.
For example, if a participant is eligible for the protocol based on corrected QT 
interval using the Fridericia formula ( QTcF), then QTc Fmust be used for 
discontinuation of this individual participant as well.
Once the QT correction formula has been chosen for a participant’s eligibility , 
the same formula must continue to be used for that participant for all QTc data 
being collected for data analysis . Safety  ECGs and other non -protocol specified 
ECGs are an exception.
The QTc should be based on single or averaged QTc values of triplicate ECG s 
obtained over a brief (e.g., 5 to 10 minute) recording period .
A participant who develops either of the bulleted criteria below will be monitored, as 
appropriate :
QTcF >500 msec
Change from baseline of QTc >60 msec 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
31For participants with underlying bundle branch block , follow the QTc evaluation
criteria listed below:
Baseline QTc with Bundle Branch Block QTc with Bundle Branch Block Evaluation 
Criteria
<450 msec >500 msec
450 to 480 msec ≥530 msec
See the SoA for data to be collected at the time of early withdrawal and follow -up and for 
any further evaluations that need to be completed.
8.1.3. Gastrointestinal Evaluation Criteria
Participants experiencing Grade 3 or Grade 4 AEs (confluent pseudomembranes or 
ulcerations OR mucosal bleeding with minor trauma; tissue necrosis OR diffuse 
spontaneous mucosal bleeding OR life -threatening consequences, e.g., aspi[INVESTIGATOR_1516], 
choking) will be followed as appropriate until resolution of the AE(s).
Furthermore, participants who experience diarrhoea or enteritis should be evaluated with 
additional fecal occult blood tests and stool cultures as deemed appropriate by  [CONTACT_249227] 5and Appendix 6.
8.1.4. Rash/Hy persensitivity Evaluation Criteria
A participant presenting with a Grade 3 AE or higher rash (diffuse macular, 
maculopapular, OR morbilliform rash with vesicles or limited number of bullae; OR 
superficial ulcerations of mucous membrane limited t o 1 site) or a Grade 2 rash (diffuse 
macular, maculopapular, or morbilliform rash; OR target lesions) with evidence of 
systemic involvement will be followed as appropriate until resolution of the AE(s).
8.2. Withdrawal from the Study
A participant may  withdraw from the stud y at an y time at his/her own request, or 
may be withdrawn at any time at the discretion of the investigator for safety , 
behavioral , compliance or administrative reasons.
If the participant withdraws consent for disclosure of future information , the sponsor 
may retain and continue to use any  data collected before such a withdrawal of 
consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in t he site 
study  records.
Refer to the SoA for data to be collected at the t ime of study  discontinuation and 
follow -up and for an y further evaluations that need to be completed.
8.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 [ADDRESS_303121] be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact [CONTACT_31823] t and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equiva lent methods). These contact [CONTACT_14316]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a prima ry reason of lost to follow -up.
9. STUDY ASSESSMENTS A ND PROC EDURES
Study  procedures and their timing are summ arized in the SoA.
Protocol waiver s or exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or 
discontinue study  treatment.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to confi rm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening 
log to record details of all participants screened and to confirm eligibility  or record 
reasons for sc reening failure, as applicable.
Procedures conduc ted as part of the participant’s routine clinical management 
(e.g., blood count) and obtained before signing of I CF may  be utilized for screening 
or baseline purposes provided the procedure met the protocol- specified criteria and 
was performed within the t ime frame defined in the SoA.
The maximum amount of blood collected from each participant over the duration of 
the study , including an y extra assessments that may  be required, will not exceed 
500mL.
Repeat or unscheduled samples may be taken for safet y reasons or for technical 
issues with the samples.
9.1. Efficacy  Assessments
Efficacy  will not be evaluated in this study .
9.2. Adverse Events
The definitions of an AE or SAE can be found in Appendix 7. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
33The investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AE sthat are serious, considered related to the study  treatment or the study ,
or that caused the participant to discont inue the study  (see Section 8).
9.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All SAE swill be collected fr om the signing of the ICF until the F ollow -Up V isitat 
the time points specified in the SoA (Section 2).
All AEs will be collected fro m the start of treatment until the F ollow -Up V isit at the 
time points specified in the SoA (Section 2).
Medical occurrences that begin before the start of study  treat ment but after obtaining 
informed consent will be recorded on the Medical History /Current Medical 
Conditions section of the electronic case report form ( eCRF) not the AE section.
All SAE swill be recorded and reported to the sponsor or designee immediately and 
under no circumstance should this exceed 24 hours, as indicated in Appendix 7. The 
investigator will submit any  updated SAE data to the sponsor within 24 hours of it 
being available.
Investigators are not obligated to activel y seek AEs or SAEs in former study  
participants. However, if the investigator learns of any SAE, including a death, at 
any time after a participant has been discharged from the study , and he/she considers 
the event to be reasonably related to the stud y treatme nt or study  participation, the 
investigator must promptly  notify  the sponsor.
The method of recording, evaluating, and assessing causality  of AEs and SAEs and 
the procedures for completing and transmitting SAE reports are provided in 
Appendix 7.
9.2.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrence. Appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?”
9.2.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SA Es, and nonserious AEs of special interest 
(as defined in Section 3.3.1 ), will be followed until the event is resolved, stabilized, 
otherwise explained, or the participant is lost to follow -up (as defined in Section 8.3). 
Further information on follow -up procedures is given in Appendix 7. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
349.2.4. Regulatory  Repor ting Requirements for SA Es
Prompt notification by  [CONTACT_11012] a SAE is essential so that 
legal obligations and ethical responsibilities towards the safet y of participants and 
the safet y of a study treatment under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  
and other regulatory  agencies about the safet y of a study treatment under clinical 
investigation. The sponsor will comply  with country -specific regulatory  
requirements relating to safet y reporting to the regulatory authority, Institutional 
Review Boards (IRB) /Independent Ethics Committees (IEC) , and investigators.
Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (SU SAR) according to local regulatory  requirements and sponsor 
policy  and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing a SAE or other 
specific safet y information e .g., summary  or listing of SAE ) from the sponsor will 
review and then file it along with the Investigator’s Brochure and will notify  the 
IRB/IEC, if appropriate according to local requirements.
9.2.5. Pregnancy
Details of all preg nancies in female participants and, if indicated, female partne rs of 
male participants will be collected after the start of study treatment and until 
completion of the Follow -up Visit .
If a pregnancy  is reported, the investigator should inform GS Kwithin 24 hours of 
learning of the pregnancy  and should follow the proc edures outlined in Appendix 2.
Abnormal pregnancy  outcomes (e .g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE.
9.3. Treatment of Overdose
There is onl y one dose of study  medica tion administered during this study , and it is 
administered at the clinic ; therefore, overdoses are not anticipated. There is no specific 
antidote for overdose with a bacterial topoisomerase inhibitor. 
In the event of an ov erdose, the investigator should:
1.Contact [CONTACT_44686] m onitor immediately .
2.Closely  monitor th e participant for AE/SAE and labor atory  abnormalities until 
gepotidacin can no longer be detected s ystemically  (at least 3days).
3.Obtain a plasma sample for PK anal ysis within 3days from the date of the last dose 
of study  treatment if requested by  [CONTACT_44686] m onitor (determined on a case -by-case 
basis).
4.Document the quantit y of the excess dose as well as the duration of the overdosing in 
the eCRF. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
359.4. Safet y Assessments
Planned time points for all sa fety assessments are provided in the SoA (Section 2).
9.4.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, assessments of the 
skin, cardiovascular , respi[INVESTIGATOR_696] , gastrointestinal and neurological s ystems. Height 
and weight will also be measured and recorded.
A brief ph ysical examination will include, at a minimum, assessments of the skin, 
lungs, cardiovascular s ystem, and abdomen (liver and spleen).
Investigators should pay  special attention to clinic al signs related to previous serious 
illnesses.
9.4.2. Vital Signs
Vital signs will be measured in a semi -supi[INVESTIGATOR_55848] [ADDRESS_303122] and will 
include sy stolic and diastolic blood pressure, and heart rate . Baseline bod y 
temperature and respi[INVESTIGATOR_2842] w ill be collected at Screening only .
9.4.3. Electrocardiograms
Single 12- lead ECG will be obtained in a semi -supi[INVESTIGATOR_55848] [ADDRESS_303123] as 
outlined in the SoA ( Section 2) usin g an ECG machine that automatically  calculates 
theheart rate and measures PR, QRS, QT, and QTc i ntervals. Refer to Section 8.1.[ADDRESS_303124] of clinical laboratory  tests to be performed and to the 
SoA (Section 2) for the timing and frequency .
The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the AE section of the 
eCRF. The laboratory  reports must be filed with the source documents. Clinically  
significant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judged by  [CONTACT_19988]’ s condition.
All laboratory  tests with val ues considered clinically  significantl y abnormal during 
the treatment period until completion of the Follow -up Visit should be repeated until 
the values return to normal or baseline or are no longer considered significantly  
abnormal b y the investigator or medical monitor. 
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the investigator, the etiology should be identified and the sponsor 
notified. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
36All protocol -required laboratory  assessments, as defined in Appendix 8, must be 
conducted in accordance with the laboratory  manual and the SoA.
9.5. Pharmacokinetics
9.5.1. Blood Sample Collection
The PK blood samples for the anal ysis of gepotidacin will be collected at the time points 
listed in the SoA (Section 2). The actual date and time of each blood sample collection 
will be recorded. The timing of PK samples may  be altered and/or PK samples may  be 
obtained at additional time points to ensure thorough PK monitoring.
For each sample, 3 mL of blood will be drawn via an indwelling catheter and/or direct 
venipuncture into tubes containing eth ylenediaminetetraacetate anticoagulant. Details of 
PK blood sample processing, storage, and shippi[INVESTIGATOR_42232].
9.5.2. Urine Sa mple Collection
The PK urine samples for the anal ysis of gepotidacin will be collected at the time points 
listed in the SoA (Section 2). The actual date and time of each urine sample collection 
will be recorded. The timing of P K samples may  be altered and/or PK samples may  be 
obtained at additional time points to ensure thorough PK monitoring.
Details of PK urine sample processing, storage, and shippi[INVESTIGATOR_249208].
9.5.3. Saliva Sample Collection
The PK saliva samples for anal ysis of gepotidacin will be collected at the time points 
listed in the SoA (Section 2). The timing of saliva samples may  be altered and/or samples 
may be obtained at additional time points to ensure thorough PK m onitoring.
Details of PK saliva sample collection, processing, storage, and shippi[INVESTIGATOR_90866].
9.5.4. Sample A nalysis
Plasma, urine, and saliva analyses will be performed under the control of [COMPANY_004] Platform 
Technologies and Science (PTS) , the details of which will be included in the SRM. 
Concentrations of gepotidacin will be determined in plasma, urine, and saliva samples 
using the currentl y appr oved bioanal ytical methodology . Raw data will be archived at the 
bioanaly tical site (detailed in the SRM).
Since plasma protein binding of gepotidacin is low (33%), onl y total drug concentrations 
will be reported for the PK anal ysis.However, in order to derive the saliva to unbound 
plasma AUC(0 -t) and AUC(0- )ratios, a correction factor of 0.[ADDRESS_303125] 
consented to participate in the genetics analy siscomponent of the study. Participation is 
optional. Participants who do not wish to participate in the genetic research may  still 
participate in the stud y.
In the event of DNA extraction failure, a replacement genetic blood sample may  be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.
See Appendix 9for information regarding genetic research. Details on processes for 
collection and shipment and destruction of these samples can be found in the SRM.
9.8. Biomarkers
Biomarkers are not evaluated in this study .
9.9. Health Economics OR Medical Resource Utilization and 
Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are 
not evaluated in this study.
10. STATISTICA L CONSIDER ATIONS
10.1. Sample Size Determination
The target sample size of 8 evaluable participants with normal hepatic function and 
8evaluable hepaticall y impaired participants in each gro upwas chosen based on 
feasibility , to address the objectives of the study . This sample size also complies with 
FDA guideline in a reduced study  design involving control participants and moderate 
hepatic impairment patients.
The between -participant coeffic ient of variations (CVb%) of PK parameters from the 
1500 mg oral tablet on Day  1 in BTZ117351 study  were 23.4%, 22. 9%, and 43.6% for 
the AUC(0 -t), AUC(0 -), and Cmax respectively .
For a CVb% of 23.4%, 22.9%, and 43.6%, and a sa mple size of 8 participants with 
normal hepatic function and 8 participants with moderate hepatic impairment, it is 
estimated that the upper limits of the 90% confidence interval (CI) for the ratio of PK  2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
38parameters of hepatic ally impaired participants to normal participants are 22.5%, 22.0%, 
and 44.4% above the corresponding point estimates for the ratios of AUC(0 -t), 
AUC(0 -), and Cmax ,respectively.
For the target sample size of 8 evaluable participants each in mild, moderate and severe 
hepatic impairment groups, the maximum the numb er of evaluable participants in this 
study  is 48 (assuming 24 matching participants with nor mal hepatic function for the 
24hepaticall y impaired participants).
10.2. Populations for A nalyses
For purposes of analy sis, the following populations are defined:
Popula tion Description
PK Population All participants who received at least [ADDRESS_303126] 1 postdose safety assessment
10.3. Statistical A nalyses
10.3.1. Pharmacokinetic A nalyses
Plasma andurine concentrations of gepotidacin will be subjected to PK analy ses using 
noncompartmental methods. Based on the individual concentration time data the 
following parameters will be estimated:
Plasma :
AUC(0 -) Area under the concentration- time curve fr om time 0 (predose) 
extrapolated to infinite time
AUC(0 -t) Area under the concentration- time curve from time 0 (predose) to time of 
last quantifiable concentration
Cmax Maximum observed concentration
λz Terminal -phase rate constant
t1/[ADDRESS_303127] occurrence of Cmax
tlag Lag time
CL/F Apparent oral clearance 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
39Vz/F Apparent volume of distribution
Urine :
Ae total Total unchanged drug (total amount of drug excreted in urin e), calculated 
by [CONTACT_249228](t1 -t2) Amount of drug excreted in urine in a time intervals for predose, 0 to 6, 
6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for 
partic ipants with hepatic impairment; and predose, 0 to 2 hours, 2 to 
4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 
36hours, and 36 to 48 hours for participants with normal hepatic function
fe% Percentage of the given dose of drug ex creted in urine, calculated as: 
fe% = (Ae total/Dose) × 100
CLr Renal clearance of drug, calculated as: Ae total/AUC(0- t)
AUC(0 -12) Area under the concentration- time curve from time 0 (predose) to 12hours
AUC(0 -24) Area under the concentration- time curv e from time 0 (predose) to 24hours
AUC(0 -48) Area under the concentration- time curve from time 0 (predose) to 48hours
Plasma concentrations andurine concentrations of gepotidacin and the associated PK 
parameters will be listed, and summary  statistics (n, mean, median, standard deviation 
[SD], minimum, maximum, and coefficient of variation [CV]) will be presented by  [CONTACT_249229]. Mean and individual plasma concentration versus time profiles will be 
presented graphicall y on linear and semilogarithmic scales.
Thenatural log-transformed plasma AUC(0 -∞) and Cmax values for gepotidacin in the 
hepatic impairment groups and normal hepatic function groups will be compared using an 
analysis of variance. Geometric mean ratios between hepatic impairment groups and 
normal hepatic function groups, and 90% CIs for the ratios of AUC(0- ∞) and Cmax for 
gepotidacin will be presented.
The natural log -transformed urine AUC(0 -48) and non-transformed CLrvalues for 
gepotidacin in the hepatic impairment groups and normal hepatic function groups will be 
compared usin g an anal ysis of variance. Geometric mean ratios between hepatic
impairment groups and normal hepatic function groups, and 90% CIs for the ratios of 
AUC(0 -48) and least square mean difference between hepatic impairment groups and 
normal hepatic function gr oups, and 90% CIs for the difference of CLr for gepotidacin 
will be presented.
Detailed descriptions of the anal yses in this study  will be presented in the Reporting and 
Analy sis Plan (RAP).
10.3.2. Safety  Analyses
All safet y anal yses will be performed on the Saf ety Population. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
40All AEs and all drug -related AEs will be listed . The incidence of AEs will be
summarized by  [CONTACT_249230]. 
Separate summaries willbe provided for AEs b y overall frequency, stud y drug -related 
AEs, and common ( 5%) AEs. Serious AEs will be summarized and listed and AEs 
leading to withdrawal from the study  will be listed. L istings for liver AEs, cardiovascular 
AEs, and rash /hypersensitivity AEs will be produced where an event hasoccurred. 
Cardiovascular -related medical conditions will be summarized .
Actual values and change from baseline for clinical chemistry  and hematology  results 
will be summarized by  [CONTACT_765]. A separate summary  for urinal ysis (dipstick) results will be 
generated. Clinical ch emistry , hematology , and urinaly sis toxicities of Grade 3 or higher 
and all clinical chemistry, hematology , and urinaly sis data for participants with toxicities 
of Grade 3 or higher will be presented in data listings.
Twelve -lead ECG findings and changes f rom baseline in 12 -lead ECG values will be 
summarized. Abnormal 12- lead ECG findings, all 12-lead ECG data for participants with 
abnormal ECG findings will be listed. I n addition, a ll quantitative ECG values of 
potential clinical importance, and all ECG values for participants with an y value of 
potential clinical importance will be listed. The frequency  of maximum postdose value 
and change from baseline ECG parameter corrected QTc interval data will be 
summarized.
Change from baseline for vital sign measure ments will be summarized by  [CONTACT_249231]. Vital signs of potential clinical importance and all vital signs for participants with 
potential clinical importance values will be presented in data listings.
Liver monitoring/stoppi[INVESTIGATOR_206319], medical cond itions for participants with aliver 
stoppi[INVESTIGATOR_249209], alcohol intake at onset of liver event, plasma concentration data for 
participants with a liver stoppi[INVESTIGATOR_249209], liver biopsy  details, and liver imaging details will 
be listed where an event has occurred.
No inferential h ypothesis testing will be performed on the safet y variables. No formal 
statistical analy sis of safety  data will be performed.
Detailed descriptions of the anal yses in this study  will be presented in the RAP.
10.3.3. Other A nalyses
Saliva :
AUC(0 -) Area under the concentration- time curve from time 0 (predose) 
extrapolated to infinite time
AUC(0 -t) Area under the concentration- time curve from time 0 (predose) to time of 
last quantifiable concentration
Cmax Maximum observed concentration
λz Terminal -phase rate constant
t1/[ADDRESS_303128] occurrence of Cmax
CL/F Apparent oral clearance
Vz/F Apparent volume of distribution
RAUC(0- t) The ratio of the AUC(0 -t) observed in saliva relative to the unbound 
AUC(0 -t) in plasma, calculated as: RAUC(0- t) = AUC(0- t) 
saliva/unbound AUC(0- t) plasma
RAUC(0- )The ratio of the AUC(0 -∞) observed in saliva relative to the unbound 
AUC(0 -∞) in plasma, calculated as: RAUC(0- ∞) = AUC(0- ∞) 
saliva/AUC(0- ∞) plasma
Saliva concentrations of gepotidacin and the associated PK parameters will be listed, and 
summary  statistics (n, mean, median, SD, minimum, maximum, and CV) will be 
presented b y time point and group . Mean and individual saliva concentration versus time 
profiles will be present ed graphicall y on linear and semilogarithmic scales.
The natural log -transformed saliva AUC(0 -∞) and Cmax values for gepotidacin in the 
hepatic impairment groups and normal hepatic function groups will be compared using an 
analysis of variance. Geometric mean ratios between hepatic impairment groups and 
normal hepatic function groups, and 90% CIs for the ratios of AUC(0- ∞) and Cmax for 
gepotidacin will be presented.
An exploratory  anal ysis will be performed to explore the relationship between saliva and 
unbound plasma concentrations. Natural log- transformed saliva gepotidacin 
concentrations ve rsus the natural log- transformed plasma gepotidacin concentrations will 
be plotted and a regression line will be fitted. A similar anal ysis will also be performed 
for the AUC(0 -), AUC(0 -t), and Cmax.
Detailed descriptions of the anal yses in this study  will be presented in the RAP.
10.3.4. Interim A nalyses
Preliminary  plasma PK, safet y, and tolerability results from participants in Part 1 will be 
reviewed by [CONTACT_249232] .
Please see Section 10.3.1 for details about the estimation of PK parameters.
Participants with mild hepatic impairment may  be enrolled in Part 2 if there is a 
significant difference in pharmacokinetics between participants with moderate hepatic 
impairment com pared with participants with normal hepatic function. Participants with 
severe hepatic impairment will be enrolled in Part 2 provided that the PK requirements 
are met (observed mean values in participants with moderate impairment do not exceed 
the thresho ld: AUC <48ghr/mL and Cmax <14g/mL) . The dose may  be adjusted for 
participants with severe hepatic impairment if either PK parameter is predicted to exceed 
the threshold.
The RAP will describe the planned interim analy ses in greater detail. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 [ADDRESS_303129], Gorrec F, et al. Ty pe IIA 
topoisomerase inhibition by  a new class of antibacterial agents. Nature . 
2010;466(7309):935-40.
Department of Health and Human Services (DHHS), Food and Drug Administration, 
Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research 
(US). Guidance for Industry:  Drug- Induced Liver Injury:  Premarketing Clinical 
Evaluation. July  2009. [28 screens]. Available from:  
http://www.fda.gov/ucm/groups/fdagov -public/@fdagov -drugs -
gen/documents/document/ucm174090.pdf
Department of Health and Human Services (DHHS), Food and Drug Administration, 
Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research 
(US). Guidance for Industry:  Phar macokinetics in Patients with I mpaired Hepatic 
Function: Study  Design, Data Anal ysis, and Impact on Dosing and Labeling. May 2003. 
[19screens]. Available from:  
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidan
ces/ucm072123.pdf
GlaxoSmithKline Document Number [ADDRESS_303130] of food on safet y, tolerabilit y, and 
pharmacokinetics following multiple doses of [COMPANY_004]2140944 in healthy  elderly  subjects. 
2015 .
GlaxoSmithKline Document Number 2015N227098_00 Study  ID BTZ115775: 
Popul ation pharmacokinetic -pharmacod ynamic analy sis of a Phase I, randomized, 
double -blinded, placebo -and moxifloxacin -controlled, [ADDRESS_303131] in adults with acetaminophen 
overdose and acute liver failure. Drug Metab Dispos 2009; 37(8):1779 -84. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
4412. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
z terminal -phase rate constant
AChE acetylcholinesterase
ADME absorption, distribution, metabolism, and excretion
AE adverse event
Ae total total unchanged drug
Ae (t1 -t2) amount of drug excreted in urine in a time interval
ALT alanine aminotransferase 
AUC area under the concentration -time curve
AUC(0 -) area under the concentration -time curve from time 0 to 
infinity
AUC(0 -t) area under the concentration -time curve from time [ADDRESS_303132] quantifiable concentration (t)
BMI body  mass index
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for Internation al Organizations of Medical 
Sciences
Clcr creatinine clearance
CL/F apparent oral clearance
CLr renal clearance
Cmax maximum observed concentration
CSR Clinical Study  Report
CVb% between -participant coefficient of variation
CYP3A4 cytochrome P450 enzy me 3A4
DMID Division of Microbiology  and Infectious Diseases
DNA deox yribonucleic acid
ECG electrocardiogram
eCRF electronic case report form
FDA Food and Drug Administration
fe% percentage of the given dose of drug excreted in urine
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GI gastrointestinal
[COMPANY_004] GlaxoSmithKline
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency virus
HRT hormone replacement therap y
ICF informed consent form
ICH Internat ional Council for Harmonisation
IEC Independent Ethics Committee 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 [ADDRESS_303133]
IUD intrauterine device
IUS intrauterine hormone -releasing s ystem
MedDRA Medical Dictionary for Regulatory  Activities
mm Hg millimeters of mercury
MSDS Material Safet y Data Sheet
msec millisecond
NIAI D National Institute of Allergy  and Infectious Disease
PK pharmacokinetic
QTc corrected QT interval; the measure of time between the start 
ofthe Q wave and the end of the T wave
QTcB corrected QT interval using the Bazett formula
QTcF corrected QT interval using the Fridericia formula
RAP Reporting and Anal ysis Plan
RAUC(0- ) ratio of the AUC(0 -∞) observed in saliva relative to the 
unbound AUC(0- ∞) in plasm a
RAUC(0- t) ratio of the AUC(0 -t) observed in saliva relative to the 
unbound AUC(0- t) in plasma
SAE serious adverse event
SoA schedule of activities
SRM Study  Reference Manual
t1/[ADDRESS_303134] upper limit of normal
Vz/F apparent volume of distribution
WOCPB women of childbearing potential
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_249233] 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
4612.2. Appendix 2: Contraceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile fol lowing menarche and until becoming post -menopausal 
unless permanentl y sterile (see below) .
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with ONE of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s: review of participant’s 
medical records, medical examination, or medical history  interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle -stimulating hormone (FSH) level in 
the postmenopausal range may  be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therap y 
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highl y effective contraception methods if they wi sh 
to continue their HRT during the stud y. Otherwise, they must discontinue HRT 
to allow confirmation of postmenopausal status before study  enrollment.
Contraception Guidance
Male participants
Male participants with female partners of child- bearing potenti al are eligible to 
participate if they  agree to ONE of the following during the protocol -defined 
time frame in Section 6.1:
Are abstinent from penile -vaginal intercourse as their usual and preferred 
lifesty le (abstinent on a long term and persistent basis) and agree to remain 
abstinent
Agree to use a male condom plus an additional method of contraception 
with a failure rate of <1% per year as described in Table 4when having 
penile -vaginal intercourse with a woman of childbearing potential  2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
47Men with a pregnant or breastfeeding partner must agree to remain abstinent 
from penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_249210] -defined ti me frame
Female participants
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly effective method of contraception consistently  and correctly  as described in 
Table 4. 
Table 4 Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependent 1
Failure rate of <1%  per year when used consistently and correctly. 
Combined (estrogen -and progestogen -containing) hormonal cont raception associated with 
inhibition of ovulation2
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulation2
injectable 
Highly Effective Methods That Are User Independent 
Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulation2
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
bilateral tubal occlusion
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used.)
Sexual abstinence 
(Sexual abstinence is considered a high ly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the pre ferred and usual lifestyle of the participant.)
NOTES: 
1. Typi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants in clinical studies.  2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
482. Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of 
the contraceptive method. In this case two highly effective methods of contraception should be utilized during 
the treatment period and until the Follow -up Visit.
Pregnancy  Testing
WOCBP should only  be included after a confirmed menstrual period and a negative 
highl y sensitive serum or urine pregnancy  test at Screening and admission to the 
clinic
Additional pregnancy  testing will be performed at the Follow- up Visit
Pregnancy  testing will be performed whenever a menstrual cy cle is missed or when 
pregnancy  is otherwise suspected 
Pregnancy  testing, with a sensitivity  of 10 mIU/mL will be performed and assay ed in 
a certified laboratory  OR and assay ed in the central laboratory  OR using the test kit 
provided b y the central laboratory / provided b y the sponsor /approved b y the 
sponsor and in accordance with instructions provided in its package insert
Collection of Pregnancy  Information
Male participants with partners who become pregnant
Investigator will attempt to collect pregnancy  information on any  male participant’s 
female partner of a male study  participant who becomes pregnant while participating 
in this study . This applies only to participants who receive study  treatment.
After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the investigator will record pregnancy information on the 
appropriate form and submit it to [COMPANY_004] within 24 hours of learning of the partner’s 
pregnancy . 
Partner will also be followed to determine the outcome of the pregnancy . 
Information on the status of the mother and child will be forwarded to [COMPANY_004] .
Generally , follow -up will be no longer than 6 to 8 weeks follow ing the estimated
delivery  date. An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure. 
Female Participants who become pregnant
Investigator will collect pregnancy  infor mation on any  female participant, who 
becomes pregnant while participating in this study.
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24 hours of learnin g of a participant's pregnancy .
Participant will be followed to de termine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to [COMPANY_004] Generall y, follow -up will not be required for longer than 6 to 
8weeks bey ond the estimated delivery date. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
49Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy  will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_249234] 7. While the investigator is not obligated to actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontaneous reporting.
Any female participant who becomes pregnant while par ticipating w ill be withdrawn 
from the study . 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
5012.3. Appendix 3: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) I nternational Ethical Guidelines
Applicable International Council for Harmonisation ( ICH)Good Clinical 
Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other relevant 
documents ( e.g., advertisements) must be submitted to an IRB/IEC by  [CONTACT_249235] d approved b y the IRB/IEC before the stud y is initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes necessary to 
eliminate an immediate hazard to study  partici pants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/IEC annually  
or more frequentl y in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as required 
by [CONTACT_1744]/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and 
all other applicable local regulations
Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to al low the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and fo r 1 year after completion of the study .
Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions 
regarding the stud y. 
Participants must be informed that their participation is voluntary . Participants or 
their legally  authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_303135] (HI PAA) 
requirements, where applicable, and the IRB/IEC or st udy center .
Themedical record must include a statement that written informed consent was 
obtained before the participant was enrolled in th e study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.
Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative. 
Participants who are rescreened are required to sign a new ICF.
The I CF may  contain a separate section that addresses the use of remaining mandatory
samples for optional exploratory  research in accordance with SOP- [COMPANY_004]F -410. The 
investigator or authorized designee will explain to each participant the objectives of the 
exploratory  research. Participants will be told that they  are free to refuse to parti cipate 
and may  withdraw their consent at any  time and for an y reason during the storage period. 
A separate signature [CONTACT_22862] a participant's agreement to allow any  
remaining specimens to be used for exploratory  research. Participants w ho decline to 
participate will not p rovide this separate signature.
Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or an y information which would make the participant identifiable 
will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by  [CONTACT_10999]. The level of 
disclosure must also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  
[CONTACT_171138], by  [CONTACT_6667]/IEC members, and by [CONTACT_55894].
Publication Policy
The results of this study  may  be published or presented at scientific meetings. If this 
is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the s ponsor will generall y 
support publication of multicenter studies only in their entiret y and not as individual 
site data. In this case, a coordinating investigator [INVESTIGATOR_159828] b y mutual 
agreement. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
52Authorship will be determined by  [CONTACT_14346].
Dissemination of Clinical Study  Data
Where required b y applicable regulatory  requirements, an investigator signatory  will 
be identified for the approval of the clinic al study  report. The investigator will be 
provided reasonable access to statistical tables, figures, and relevant reports and will 
have the opportunit y to review the complete study results at a [COMPANY_004] site or other 
mutually -agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results . 
The investigator is encouraged to share the summary  results with the study  
participants, as appropriate.
Data Quality  Assurance
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (e.g., laboratory  
data). The investigator is responsible for verifying that data entries are accurate and 
correct b y physically or electronicall y signing the CRF. 
The investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safet y and rights of participants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other stud y agreements, I CH GCP, and all applicable 
regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this study  
must be retained b y the investigator for 25years from the issue of the final Clinical 
Study  Report (CSR) / equivalent summary unless local regulations or institutional 
policies require a longer retention period. No records may  be destroy ed during the 
retention period without the written approval of the sponsor. No records may be 
transferred to another locatio n or part y without written notification to the sponsor. 
Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must  2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 [ADDRESS_303136] be 
available.
Definition of what constitutes source data can be found in the SR M.
Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at an y 
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants b y the investigator
Discontinua tion of further study  treatment development 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
5412.4. Appendix 4: Liver Safety : Required A ctions and Follow -up 
Assessments
Phase I Liver chemistry  evaluation criteria have been designed to assure participant
safet y and to evaluate liver event etiology  (in alignment with the FDA premarketing 
clinical liver safety  guid ance).
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf .
Phase I liver chemistry evaluation criteria and required follow up assessments for 
healthy partic ipants only
Liver Chemistry Evaluation Criteria 
ALT- absoluteALT ≥3× ULN
If ALT ≥3× ULN AND bilirubin1,22× ULN (>35% direct bilirubin) or INR>1.5, 
Report as an SAE.
See additional Actions and Follow Up Assessments listed below
Required Actions a nd Follow up Assessments 
Actions Follow Up Assessments
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF, and complete 
anSAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessme nts 
Monitor the participant until liver chemistries 
resolve, stabilise, or return to within baseline
(see MONITORING below)
MONITORING:
If ALT ≥3× ULN AND bilirubin 2× ULN or 
INR>1.5
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver even t follow up assessments within 
24hrs
Monitor participants twice weekly until liver 
chemistries resolve, stabili ze or return to 
within baseline
A specialist or hepatology consultation is Viral hepatitis serology3
Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downwar d 
trend
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total bilirubin
2 × U LN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of l iver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form 
including acetaminophen, herbal remedies, 
other over the counter medications.
Record alcohol use on the liver event  2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
55Liver Chemistry Evaluation Criteria 
recommended
If ALT ≥3 × ULN AND bilirubin <2 × ULN and 
INR≤1.5:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) andperform
liver even t follow up asses sments within 
24to 72 hrs
Monitor participants weekly until liver 
chemistries resolve, stabilize or return to 
within baselinealcohol intake case report form
If ALT ≥3×ULN AND bilirubin 2×ULN or 
INR >1.5 :
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulin s.
Serum acetaminophen adduct high 
performance l iquid chromatography 
(HPLC) assay (quantifies potential 
acetaminophen contribution to liver injury 
in participants with definite or likely 
acetaminophen use in the preceding week 
[James, 2009].
Liver imaging (ultrasoun d, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fraction ation is not 
immediately available, discontinue study treatment for that participant if ALT 3 × ULN and bilirubin 2× ULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary bilirubin on 
dipstick, indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3× ULN and bilirubin 2× ULN (>35% direct bilirubin) or ALT  3× ULN and INR >1.5, if INR 
measured, which may indicate severe liver injury (possible ‘Hy’s Law’), mus t be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated will 
not apply to participants receiving anticoagulants
3. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot test ing); Hepatitis E IgM antibody 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
5612.5. Appendix 5: Follow -up for Gastrointestinal Findings
Participants who experience diarrhoea or enteritis should be evaluated with additional 
fecal occult blood tests and stool cultures as deemed appropriate by  [CONTACT_093]. Any  
participant with a positive fecal occult blood te st should be referred to a 
gastroenterologist for further evaluation at the discretion of the investigator.
Participants who experience an AE of diarrhoea or enteritis should have additional fecal 
occult blood testing, as well as a routine stool culture pe rformed, which may  include the 
recovery  of pathogenic bacteria such as Salmonella, Shigella , Campylobacter, Yersinia, 
Vibrio, Staphylococcus aureus, Escherichia coli 0157, and enterohemorrhagic 
Escherichia coli .
In addition, if the participant meets the cl inical criteria outlined in Appendix 6, 
Clostridium difficile toxin detection should be conducted. 
Note: Additional testing is at the discretion of the investigator if it is believed the 
GIsigns/s ymptoms are due to cholinergic effec ts and/or if the GI signs/s ymptoms occur 
within 24 hours of the infusion. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
5712.6. Appendix 6: Clostridium Difficile Testing Procedure and 
Algorithm
 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
5812.7. Appendix 7: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Defini tion of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study treatment, whether or not considered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavora ble and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , serum chemistry , or urinaly sis) or 
other safet y assessments ( e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator ( i.e.,not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment a dministration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose ta ken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.
Events NOT Meeting the AE Defini tion 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The dis ease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure ( e.g., endoscopy , appendectom y): the condition th at  2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
59leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met ( e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to pr ogression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_91260] p articipant has been detained (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur du ring hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_227522] a pre -existing condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life f unctions.
This definition is not intend ed to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
and accidental trauma ( e.g., sprained ankle) which may  interfere with or preven t 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may   2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
60not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_249211]. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in ho spi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
g. Is associated with liver injury andimpaired liver function (healthy participants 
only) defined as:
ALT 3 × ULN and total bilirubin*2 × ULN (>35% direct), or
ALT 3 × ULN and INR**>1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick. I f fractionation is unavailable and ALT 3 × ULN 
and total bilirubin  2 × ULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
participants receiving anticoagulants. If an INR measurement is obtained, the value is to 
be recorded on the SAE Form.
Recording A E and SA E
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation ( e.g., hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004] . In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y according to the US National Institute of Allergy  and Infectious 
Disease (NIAID) Division of Microbiology  and Infectious Diseases ( DMID )criteria  2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
61for adult toxicity  assessment ( Appendix 10).
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment a nd 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical ju dgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment 
administration will be considered and investigated.
The investigator will also consult the Investigator’s Brochure and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provide d an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to [COMPANY_004] .However, it is very 
important that the investigator always make an assessment of causal ity for 
every event before the initial transmission of the SAE data to [COMPANY_004] .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_31859]/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
If a participant dies during participation in the study  or during a recognized follow -
up period, the investigator will provide [COMPANY_004] with a cop y of an y post-mortem 
findings including histopathology .
New or updated information will be recorded in the originally  completed CRF. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
62The investigator will submit any  updated SAE data to [COMPANY_004] within 24 hours of 
receipt of the information.
Reporting of SA E to [COMPANY_004]
SAE Reporting to [COMPANY_004] via Electronic Data Collection Tool
The primary  mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool.
If the electronic s ystem is unavailable , then the site will use the paper SAE data 
collection tool (see next section ) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
The investigator or medically -qualified sub -investigator must show evidence within 
the eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to the investigational product ( IP)/study participation 
(causalit y) within 72 hours of SAE entry  into the eCRF.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
Ifa site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to th e [COMPANY_003] medical monitor by  [CONTACT_756].
Contacts for SAE reporting can be fo und at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774] .
SAE Reporting to [COMPANY_004] via Paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the [COMPANY_003] medical monitor .
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_249236].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be f ound at the beginning of th is protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
6312.8. Appendix 8: Clinical Laboratory  Tests
Hematology , serum chemistry , urinal ysis,and additional parameters to be tested are listed 
inTable 5.
The tests detailed in Table 5will be perform ed by [CONTACT_2237] . 
Local laboratory  results are only  required in the event that the central laboratory  
results are not available in time for either stud y treatment administration and/or 
respo nse evaluation. If a local sample is required, it is important that the sample for 
central anal ysis is obtained at the same time.
Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section 6of the protocol.
Additional tests may  be performed at an y time during the stud y as determined 
necessary  by [CONTACT_43215].
Table 5 Protocol -Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count RBC Indices:
MCV
MCH
MCHCWBC count with 
Differential :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Clinical 
Chemistry1BUN Potassium AST Total and direct bilirubin
Creatinine Sodium ALT Total Protein
Glucose Calcium Alkaline phosphatase Albumin
Creatine kinase
Routine 
UrinalysisSpecific gravity
pH, glucose, protein, blood, ketones by [CONTACT_5230]
Microscopic examination (if blood or protein is abnormal)
Other Screening 
TestsClcr (Section 6.2)
Prothrombin time and prothrombin time international normalized ratio (INR) 
(Section 7.3)
Hepatitis B surface antigen, hepatitis C virus antibody, a nd human 
immunodeficiency virus
Follicle -stimulating hormone and estradiol (as needed in women of 
non-childbearing potential only)
Alcohol (via urine, blood alcohol, or breathalyzer test) and drug screen (via serum, 
urine, or saliva) to includ e, at a minimum: amphetamines, barbiturates, cocaine, 
opi[INVESTIGATOR_858], cannabinoids, and benzodiazepi[INVESTIGATOR_1651]) 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
64Laboratory 
AssessmentsParameters
Serum or urine human chorionic gonadotropin (hCG) pregnancy test (as needed 
for women of childbearing potential)[ADDRESS_303137] be entered int o the CRF.
NOTES :
1.Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments after liver 
stoppi[INVESTIGATOR_31777] 8.1and Appendix 4All events of ALT 3 × upper limit 
of normal ( ULN)and bilirubin 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and INR >1.5, if INR 
measured, which may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis).
2.Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_216483]/IEC. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
6512.9. Appendix 9: Genetics
USE/ANALYSIS OF DNA
Genetic variation may  impact a participant’ s response to therap y, susceptibility , 
severit y and progression of disease. Variable response to therap y ma y be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mechanism of action of the drug; disease etiology; and/or molecular 
subty pe of the disease being treated. Therefore, where local regulations and I RB/IEC
allow, a blood sample will be collected for D NA analy sis.
DNA samples will be used for research related to gepotidacin . They  may  also be 
used to deve lop tests/assay s including diagnostic tests) related to gepotidacin or 
study  treatments of this drug class. Genetic research may  consist of the analy sis of 
one or more candidate genes or the analy sis of genetic markers throughout the 
genome [or anal ysis of the entire genome] (as appropriate) .
DNA samples will be analy zedif it is hy pothesized that this may  help further 
understand the clinical data. 
The samples may  be analy zedas part of a multi -study  assessment of genetic factors 
involved in the respon se to gepotidacin or study treatments of this class. The results 
of genetic anal yses may  be reported in the clinical study  report or in a separate study  
summary .
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained while researc h on gepotidacin (or st udy treatments of 
this class) continues but no longer than [ADDRESS_303138] visit or 
other period as per local requirements. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117 352
6612.10. Appendix 10: DMID A dult Toxicity  Tables for A E 
Assessment
ESTIMATING SEVERITY GRADE :For abnormalities NOT found elsewhere in the 
Toxicity  Tables, use the scale below to estimate grade of severit y:
GRADE 1 MildTransient or mild discomfort (<48 hours); no medical 
intervention/th erapy required
GRADE 2 ModerateMild to moderate limitation in activity –some assistance may 
be needed; no or minimal medical intervention/therapy 
required
GRADE 3 SevereMarked limitation in activity, some assistance usually 
required; medical intervent ion/therapy required, 
hospi[INVESTIGATOR_249212] 4 Life-threateningExtreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, 
hospi[INVESTIGATOR_249213] -THREATE NING AEs: ANY clinical event deemed by  [CONTACT_126745]-threatening should be considered a grade 4 event. 
Clinical events considered to be serious or life -threatening include, but are not limited to: 
seizures, coma, tetan y, diabetic ketoacidosis, disseminated intravascular coagulation, 
diffuse petechiae, paral ysis, acute ps ychosis, and severe depression.
COMMENTS REGARDING THE USE OF THESE TABLES
Standardized and commonly  used toxicity  tables (Division of AIDS, N ational Cancer 
Institut e’s Common Toxicity  Criteria , and World Health Organization ) have been 
adapted for use b y the NIAID DMID and modified to better meet the needs of 
participants in DMID trials.
For parameters not included in the following Toxicity  Tables, sites should refer to the 
“Guide for Estimating Severity  Grade” located above.
Criteria are ge nerall y grouped by  [CONTACT_44749].
Some protocols may  have additional protocol specific grading criteria, which will 
supersede the use of these tables for specified crite ria. 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
67HEMATOL OGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin 9.5 to 10.5 gm/dL 8.0 to 9.4 gm/dL 6.5 to 7.9 gm/dL <6.5 gm/dL
Absolute Neutrophil Count 1000 to 1500 /mm3 750 to 999 /mm3 500 to 749 /mm3 <500 /mm3
Platelets 75,000 to 99,999 /mm3 50,000 to 74,999 /mm3 20,000 to 49,999 /mm3 <20,000 /mm3
White Blood Cells 11,000 to 13,000 /mm3 13,000 to 15,000 /mm3 15,000 to 30,000 /mm3 >30,000 or <1000 /mm3
% Polymorphonuclear Leukocytes + 
Band Cells>80% 90 to 95% >95% N/A
Abnormal FibrinogenLow: 100 to 200 mg/dL
High: 400 to 600 mg/dLLow: <100 mg/dL
High: >600 mg/dLLow: <50 mg/dL
High: N/AFibrinogen associated with gross bleeding or 
with disseminated coagulation
Fibrin Split Product 20 to 40 mcg/mL 41 to 50 mcg/mL 51 to 60 mcg/dL >60mcg/dL
Prothrombin Time (PT) 1.01 to 1.25 ULN 1.26 to 1.5 ULN 1.51 to 3.0 ULN >3ULN
Activated Partial Thromboplastin (APTT) 1.01 to 1.66 ULN 1.67 to 2.33 ULN 2.34 to 3 ULN >3ULN
Methemoglobin 5.0 to 9.9% 10.0 to 14.9% 15.0 to 19.9% >20%
N/A = not applicable; ULN = upper limit of normal.  
 
 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
68CHEMISTRIES
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to 135 mEq/L 123 to 129 mEq/L 116 to 122 mEq/L<116 mEq/L or abnormal sodium withmental 
status changes or seizures
Hypernatremia 146 to 150 mEq/L 151 to 157 mEq/ L 158 to 165 mEq/L>165 mEq/L or abnormal sodium withmental 
status changes or seizures
Hypokalemia 3.0 to 3.4 mEq/L 2.5 to 2.9 mEq/L2.0 to 2.4 mEq/L or intensive 
replacement therapy of 
hospi[INVESTIGATOR_91536]<2.0 mEq/L or abnormal potassium with
pares is, ileus, or life -threatening arrhythmia
Hyperkalemia 5.6 to 6.0 mEq/L 6.1 to 6.5 mEq/L 6.6 to 7.0 mEq/L>7.0 mEq/L or abnormal potassium with
life-threatening arrhythmia
Hypoglycemia 55 to 64 mg/dL 40 to 54 mg/dL 30 to 39 mg/dL<30mg/dL or abnormal gl ucose withmental 
status changes or coma
Hyperglycemia
(nonfasting and no prior 
diabetes)116 to 160 mg/dL 161 to 250 mg/dL 251 to 500 mg/dL>500 mg/dL or abnormal glucose with
ketoacidosis or seizures
Hypocalcemia
(corrected for albumin)8.4 to 7.8 mg/dL 7.7 to 7.0 mg/dL 6.9 to 6.1 mg/dL<6.1 mg/dL or abnormal calcium with
life-threatening arrhythmia or tetany
Hypercalcemia
(corrected for albumin)10.6 to 11.5 mg/dL 11.6 to 12.5 mg/dL 12.6 to 13.5 mg/dL>13.5 mg/dL or abnormal calcium with
life-threaten ing arrhythmia
Hypomagnesemia 1.4 to 1.2 mEq/L 1.1 to 0.9 mEq/L 0.8 to 0.6 mEq/L<0.6 mEq/L or abnormal magnesium with
life-threatening arrhythmia
Hypophosphatemia 2.0 to 2.4 mg/dL1.5 to 1.9 mg/dL or 
replacement Rx required1.0 to 1.4 mg/dL
intensive th erapy or hospi[INVESTIGATOR_126693]<1.0 mg/dL or abnormal phosphate with
life-threatening arrhythmia
Hyperbilirubinemia (when 
accompanied by [CONTACT_126746])1.1 to <1.25 ULN 1.25 to <1.5 ULN 1.5 to 1.75 ULN >1.75 ULN
Hyperbilirubinemia (when other 
liver function tests are in the 
normal range)1.1 to <1.5 ULN 1.5 to <2.0 ULN 2.0 to 3.0 ULN >3.0ULN
Blood urea nitrogen 1.25 to 2.5 ULN 2.6 to 5 ULN 5.1 to 10 ULN >10ULN
Hyperuricemia (uric acid) 7.5 to 10. 0mg/dL 10.1 to 12.0 mg/dL 12.1 to 15.0 mg/dL >15.0 mg/dL
Creatinine 1.1 to 1.5 ULN 1.6 to 3.0 ULN 3.1 to 6.0 ULN >6ULN or dialysis required
Rx = therapy; ULN = upper limit of normal. 
 
 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
69ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
Aspartate amino transferase (AST) 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Alanine aminotransferase (ALT) 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Gamma to glutamyl transferase (GGT) 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0to 8.0 ULN >8.0ULN
Alkaline Phosphatase 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Amylase 1.1 to 1.5 ULN 1.6 to 2.0 ULN 2.1 to 5.0 ULN >5.1ULN
Lipase 1.1 to 1.5 ULN 1.6 to 2.0 ULN 2.1 to 5.0 ULN >5.1ULN
ULN = upper limit of normal.
URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Proteinuria1+ or
200mg to 1 gm loss/day2 to 3+ or
1 to 2 gm loss/day4+ or
2 to 3.5 gm loss/dayNephrotic syndrome or
>3.5 gm loss/day
HematuriaMicroscopic only
<10RBC/hpfGross, no clots
>10RBC/hpfGross, with or without clots,
or red blood cells castsObstructive or 
required transfusion
hpf= high powered field; RBC = red blood cells. 
 
 2018N388749_00
2017N352027_00 CONFIDENTIA L
BTZ117352
70CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac rhythmN/A Asymptomatic, tra nsient signs, no 
Rx requiredRecurrent/persistent; symptomatic 
Rx requiredUnstable dysrhythmia; 
hospi[INVESTIGATOR_249214] >20 mmHg;
no treatment Recurrent, chronic increase 
>20mmHg;
treatment required Acute treatment required; 
outpatient treatment or 
hospi[INVESTIGATOR_249215] 
<20beat/min or decreased by 
<10mmHg systolic BP.
No treatm ent requiredSymptoms due to orthostatic 
hypotension or BP decreased by 
<20mmHg systolic; correctable 
with oral fluid treatmentRequires IV fluids;
no hospi[INVESTIGATOR_249216] <60 mmHg 
or end organ damage or shock;
requires hospit alization and 
vasopressor treatment
Pericarditis Minimal effusion Mild/moderate asymptomatic 
effusion, no treatmentSymptomatic effusion; pain; EKG 
changesTamponade; pericardiocentesis or 
surgery required
Hemorrhage, Blood Loss Microscopic/occult Mild, no transfusion Gross blood loss; 
1 to 2 units transfusedMassive blood loss; >3 units 
transfused
N/A = not applicable; Rx = therapy; BP = blood pressure; IV = intravenous; EKG = electrocardiogram
RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
Cough Transient; no treatment Persistent cough; treatment responsive Paroxysmal cough; uncontrolled with treatment N/A
Bronchospasm, 
AcuteTransient; no treatment; 
FEV 170 to 80% of peak flowRequires treatment; normalizes with 
bronchodilator; FEV 150 to 70 % of p eak 
flowNo normalization with bronchodilator; FEV 125 
to 50% of peak flow; or retractions presentCyanosis: FEV 1<25%  of peak 
flow; or intubation necessary
DyspneaDyspnea on exertion Dyspnea with normal activity Dyspnea at rest Dyspnea requiring oxygen 
therapy
N/A = not applicable; FEV 1= forced expi[INVESTIGATOR_3741] 1 second. 
 
 2018N388749_00
2017N352 027_00 CONFIDENTIA L
BTZ117352
71GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
NauseaMild or transient; maintains 
reasonable intakeModerate discomfort; intake 
decreased significantly; some 
activity limi tedNo significant intake; requires IV fluids Hospi[INVESTIGATOR_249217]1 epi[INVESTIGATOR_85712] 24 hours 2 to 5 epi[INVESTIGATOR_11630] 24 hours >6 epi[INVESTIGATOR_11630] 24 hours or needing IV 
fluidsPhysiologic consequences requiring 
hospi[INVESTIGATOR_249218]; 3 to 
4loose stools/day or mild 
diarrhea lasting <1 weekModerate or persistent; 5 to 
7loose stools/day or diarrhea 
lasting >1 week>7 loose stools/day or bloody diarrhea; or 
orthostatic hypotension or electrolyte 
imbalance or >2L IV fluids requiredHypotensive shock or physiologic 
consequences requiring hospi[INVESTIGATOR_249219]/
DysphagiaMild discomfort; no difficulty 
swallowingSome limits on eating/drinking Eating/talking very limited; unable to 
swallow solid foodsUnable to drink fluids; requires IV fluids
IV = intravenous.
NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Neuro- CerebellarSlight incoordination 
dysdiadochokinesisIntention tremor, dysmetria, slurred 
speech; nystagmusLocomotor ataxia Incapacitated
PsychiatricMild anxiety or depression Moderate anxiety or depression; 
therapy require d; change in normal 
routineSevere mood changes requiring therapy; 
or suicidal ideation; or aggressive 
ideationAcute psychosis requiring 
hospi[INVESTIGATOR_059]; or suicidal 
gesture/attempt or hallucinations
Muscle strengthSubjective weakness; no objective 
symp toms/signsMild objective signs/symptoms; no 
decrease in functionObjective weakness; function limited Paralysis
Paresthesia
(burning, tingling, etc.)Mild discomfort; no treatment 
requiredModerate discomfort; non -narcotic 
analgesia requiredSevere disc omfort; or narcotic analgesia 
required with symptomatic improvementIncapacitating; or not responsive 
to narcotic analgesia
NeurosensoryMild impairment in sensation 
(decreased sensation, e.g., 
vibratory, pi[INVESTIGATOR_29107], hot/cold in great 
toes) in focal area or symmetrical 
distribution; or change in taste, 
smell, vision, and/or hearingModerate impairment (moderately 
decreased sensation, e.g., 
vibratory, pi[INVESTIGATOR_29107], hot/cold to 
ankles) and/or joint position or mild 
impairment that is not symmetricalSevere impairm ent (decreased or loss of 
sensation to knees or wrists) or loss of 
sensation of at least moderate degree in 
multiple different body areas (i.e., upper 
and lower extremities)Sensory loss involves limbs and 
trunk; paralysis; or seizures 
 
 2018N388749_00
2017N352 027_00 CONFIDENTIA L
BTZ117352
72MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia 
(joint pain)Mild pain not interfering with function Moderate pain, analgesics and/or pain 
interfering with function but not with ADLSevere paid; pain and/or analgesics 
interfering with ADLDisabling pain
Arthr itisMild pain with inflammation, erythema or 
joint swelling, but not interfering with 
functionModerate pain with inflammation, erythema or 
joint swelling; interfering with function but not 
with ADLSevere pain with inflammation, erythema 
or joint swellin g, and interfering with ADLPermanent and/or 
disabling joint 
destruction
MyalgiaMyalgia with no limitation of activity Muscle tenderness (at other than injection site) 
or with moderate impairment of activitySevere muscle tenderness with marked 
impairmen t of activityFrank myonecrosis
ADL = activities of daily living.
SKIN
Grade 1 Grade 2 Grade 3 Grade 4
MucocutaneousErythema; pruritus Diffuse, maculo papular rash, dry 
desquamationVesiculation or moist 
desquamation or ulcerationExfoliative derma titis, mucous membrane 
involvement or erythema, multiforme or suspected 
Stevens- Johnson or necrosis requiring surgery
Induration <15mm 15 to 30 mm >30mm N/A
Erythema <15mm 15 to 30 mm >30mm N/A
Edema <15mm 15 to 30 mm >30mm N/A
Rash at injection site <15mm 15 to 30 mm >30mm N/A
Pruritus Slight itching at injection site Moderate itching at injection extremity Itching over entire body N/A
N/A = not applicable.
SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Allergic reaction Pruritus without rash Localized urticarial Generalized urticarial; angioedema Anaphylaxis
HeadacheMild, no treatment required Transient, moderate; treatment required Severe; responds to initial narcotic 
therapyIntractable; requires repeated 
narcotic therapy
Fever: oral 37.7Cto 38.5 C or 100.0 Fto 101.5 F 38.6Cto 39.5 C or 101.6 Fto 102.9 F 39.6Cto 40.5 C or 103 Fto 105 F >40 C or >105 F
FatigueNormal activity reduced <48 hours Normal activity decreased 25 to 50%; 
>48 hoursNormal activity decreased >50 %; 
cannot w orkUnable to care for self 
 
 2018N388749_00